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HIV-1 enters the CNS soon after initial systemic infection. HIV-1 can induce a wide range of 
neurological deficits, collectively known as HIV-1-associated neurocognitive disorders (HAND). 
Mature neurons are not infected by HIV-1; instead, infected and/or activated glial cells release 
various viral and cellular factors that induce direct and/or indirect neuronal toxicity, leading to 
HAND. Injection drug abuse is a significant risk factor for HIV-infection, and opiate drug 
abusers show increased HIV-neuropathology, even with anti-retroviral treatments. Our previous 
work has largely modeled HIV-neuropathology using the individual viral proteins Tat or gp120, 
with murine striatal neurons as targets. To model disease processes more closely, the current 
study uses supernatant from HIV-1-infected cells.  
Supernatant from HIV-1SF162 (R5-tropic)-infected differentiated-U937 cells (HIV
+
sup) was 
collected and p24 level was measured by ELISA to assess the infection. We assessed HIV
+
sup 
effects on neuronal survival and neurite growth/pruning with or without concurrent exposure to 
 
 
 
 
morphine, an opiate that preferentially acts through µ-opioid receptors. Effects of HIV
+
sup ± 
morphine were assessed on neuronal populations, and also by time-lapse imaging of individual 
cells. HIV
+
sup caused dose-dependent toxicity over a range of p24 levels (10-500 pg/ml). 
Significant interactions occurred with morphine at lower p24 levels (10 and 25 pg/ml). In the 
presence of glia, selective neurotoxic measures were significantly enhanced and interactions with 
morphine were also augmented. Importantly, the arrest of neurite growth that occurred with 
exposure to HIV
+
sup was reversible unless neurons were continuously exposed to morphine. 
Thus, while reducing HIV-infection levels may be protective, ongoing exposure to opiates may 
limit recovery. 
During early stage of HIV-infection R5-tropic viruses are predominant, but during later stages of 
disease X4-tropic viruses are more predominant; co-receptor usage switch from CCR5 to 
CXCR4 is crucial in disease progression to AIDS. Some previous studies have shown that drugs 
of abuse interact with virus or viral proteins in strain/tropism-dependent manner. Therefore, we 
also assessed neurotoxic effects and interactions with opiates by supernatant from HIV-1LAI (X4-
tropic)-infected H9 cells. Neurotoxic effects and the interactions with opiates of HIV-1LAI-
supernatant are quantitatively similar to that of HIV-1SF162. Surprisingly, the cytokine/chemokine 
release profile of HIV-1LAI-infected H9 cells is similar to that of HIV-1SF162-infected U937 cells. 
Only in the presence of glia, HIV-1LAI virion induced neurotoxic effects, but no interactions with 
morphine were seen. Also our studies have shown that HIV-1LAI virions are slightly more 
neurotoxic than HIV-1SF162. Altogether, largely our results suggest that HIV
+
sup mediated 
neurotoxicity and the interactions with opiates are majorly attributed to cytotoxic factors released 
from infected and activated cells instead of viral strain specific factors. 
 
 
 
 
Although there is a correlation between opiate drug abuse and progression of HAND, the 
mechanisms that underlie interactions between HIV-1 and opiates remain obscure. Previous 
studies have shown that HIV-1 induces neurotoxic effects through abnormal activation of 
GSK3β. Interestingly, expression of GSK3β has shown to be elevated in the brains of young 
opiate abusers suggesting that GSK3β is also linked to neuropathology seen with opiate abusing 
patients. Thus, we hypothesized that GSK3β activation is a point of convergence for HIV- and 
opiate-mediated interactive neurotoxic effects. Cultures of striatal neurons were treated with 
HIV
+
sup (R5-tropic), in the presence or absence of morphine and GSK3β inhibitors. Our results 
show that multiple GSK3β inhibitors significantly reduce HIV-1-mediated neurotoxic outcomes, 
and also negate interactions with morphine that result in cell death. This suggests that GSK3β-
activation is an important point of convergence and a potential therapeutic target for HIV- and 
opiate-mediated neurocognitive deficits.  
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CHAPTER 1 
Introduction 
HIV/AIDS 
Epidemiology of HIV/AIDS 
Human immunodeficiency virus (HIV) infects immune system cells, primarily CD4
+
 T cells and 
monocytes/macrophages. HIV infection dysregulates normal immune system functioning and 
leads to acquired immunodeficiency syndrome (AIDS) [1-3]. Worldwide about 35.3 million 
people are infected with HIV. In 2012, 2.3 million people were newly infected with HIV, and 1.6 
million died due to AIDS [4]. Due to limited access to combination antiretroviral therapy 
(cART), AIDS pandemic continues to spread unchecked in many underdeveloped countries; sub-
Saharan Africa is badly affected region, where around 25 million people are living with HIV 
infection. In 2012, in these countries nearly 1.6 million people were newly infected with HIV 
and 1.2 million died due to AIDS. AIDS epidemic has eroded the socioeconomic stability of 
these countries. 
HIV genome and life cycle 
HIV has been characterized into two types, HIV type 1 (HIV-1) and type 2 (HIV-2). HIV-1 is 
relatively more pathogenic and thus is spread worldwide, while HIV-2 is relatively less virulent 
and thus is restricted to limited parts of the world [5, 6]. HIV-1 has single stranded RNA genome 
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consisting of 9 genes. The gag genomic region encodes for gag polyprotein, which is mainly 
processed to p17 (matrix protein, MA), p24 (capsid protein, CA), p7 (nucleocaspid protein, NC), 
and p6 proteins, by the viral protease. The pol gene encodes for reverse transcriptase (RT), 
RNase H, integrase and protease. The env gene encodes for precursor glycoprotein gp160, which 
is processed to surface glycoprotein gp120 and transmembrane glycoprotein gp41, by furin, a 
host cell protease. Remaining 6 genes (tat, rev, nef, vpr, vif, vpu) encode for regulatory proteins, 
involved in regulation of viral replication and release [3, 7-9]. 
HIV-1 surface glycoprotein gp120 binds/interacts to CD4 and a co-receptor, usually either C-C 
chemokine receptor type 5 (CCR5) or C-X-C chemokine receptor type 4 (CXCR4) on the surface 
of host cells. After binding/interaction, conformational changes in gp120 and gp41 enable virus 
to fuse with host cells and release its genetic material into host cells. RT with help of host co-
factors transcribes DNA from RNA template by process called reverse transcription. Integrase 
integrates reverse-transcribed viral genome (DNA genome) into host chromosome. Following 
integration, the virus uses host cell machinery to transcribe and/or translate its genetic material 
and proteins. The Viral protease processes viral precursor proteins. Viral proteins and genetic 
materials assemble at the host cell membrane and bud out as new virions, ready for next cycle of 
infection. In some cases, following integration into the host genome, virus can remain latent for 
prolonged periods [3, 7-9]. 
HIV-1 tropism 
The preference of HIV-1 gp120 for the co-receptors, either CCR5 or CXCR4, defines viral-
tropism [10-13]. M-tropic (macrophage/monocyte tropic, R5-tropic) strains of HIV-1 use β-
chemokine receptor, CCR5, to attach to host cells, and thus they mainly infect monocytes and/or 
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macrophages. T-tropic (T-cell tropic, X4-tropic) strains have preference for α-chemokine 
receptor, CXCR4, and thus they mainly infect CD4
+
 T cells. Some strains of HIV-1 do not have 
preference for either CCR5 or CXCR4, and are known as dual-tropic (X4R5-tropic) strains. 
Previous studies have shown that also some other chemokine receptors, such as CCR2, CCR3 
and C-X3-C chemokine receptor 1 (CX3CR1, fractalkine receptor), can serve as co-receptors for 
viral attachment/binding at host cell surface [14-18]. 
NeuroAIDS 
Invasion of HIV-1 into CNS 
HIV-1 not only disrupts normal immune system functioning, but can also induce neurological 
complications, known as neuroAIDS. The blood brain barrier (BBB) is a tight, cohesive barrier 
between blood and brain. The BBB regulates influx of selective compounds from blood in 
capillaries to brain parenchyma, important for homeostasis and proper functioning of the brain 
[19-21]. Also the BBB protects central nervous system (CNS) from many infections and toxic 
insults in blood/plasma. Unlike a variety of blood-borne insults, HIV-1 overcomes this tight 
barrier and can invade the brain. HIV-1 can enter into the CNS soon after an initial systemic 
infection [22-24]. The exact route/mechanism for HIV-1 entry across BBB is not known. There 
are three hypotheses for route/mechanism of viral infiltration into CNS [22, 25]. The first 
hypothesis suggests that HIV-1 may invade into CNS as a passenger within infected leukocytes, 
which normally traffic across the BBB as a part of immune surveillance of the brain, known as 
‘trojan horse’ hypothesis [26-28]. The second hypothesis suggests that activated and/or infected 
immune cells release various cytokines/chemokines and viral proteins, which can disrupt BBB 
integrity [29-32]. Thus, cell free virus particles may cross through compromised BBB and invade 
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into CNS. Alternatively, studies in cell cultures have shown that brain microvascular endothelial 
cells (BMVECs) can internalize virus particles into intracellular vacuoles, traffic these vacuoles 
via transcytosis, and release them at other side of the barrier [33-35]. Thus, it can be predicted 
that HIV-1 may traverse the BBB via transcytosis through BMVECs. The third hypothesis 
suggests that HIV-1 may invade into CNS via transmission by infected BMVECs because some 
in vitro studies have shown that these cells are capable of transmitting virus to other cells by 
direct cell-to-cell contact [36].  
HIV-1 infection of cells in the brain 
The Perivascular region of the brain is closely  interfaces with the periphery, thus it comes in 
early and direct contact with HIV-1-infected leukocytes and/or free virus particles that cross 
through the BBB. Cells in this region of the brain, mainly perivascular macrophages, microglia 
and astrocytes, are the major site of viral infection. Unlike other resident cells within the brain, 
microglia are derived from mesoderm; microglia are also known as immune component of the 
brain [37-39]. Macrophages and microglia express CD4 and CCR5, the major receptor and co-
receptor for HIV-1 entry [40-42]. Various studies in cell cultures have shown that primary 
macrophages and microglia are productively infected with HIV-1 [43-46]. 
Markers of viral infection, proteins and nucleic acids, have been detected in GFAP positive 
astrocytes [47-50], suggesting that these cells can be infected with HIV-1. Several in vitro 
studies with primary cells and tumor derived cell lines have confirmed that astrocytes can be 
infected with HIV-1 [51-53]. However, after initial acute productive infection their viral 
production is reduced to very low or undetectable levels [52, 54]. But virus production in 
persistently infected astrocytes can be transiently activated by treatment with pro-inflammatory 
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stimuli [52, 54, 55]. Also, it has been shown that persistently infected astrocytes initiate viral 
production in co-cultured monocytes/macrophages and T-cells [52, 54, 56]. Thus, it can be 
concluded that astrocytes act as a viral reservoirs. 
Other resident cells of the CNS, oligodendrocytes and neurons, are rarely infected with HIV-1. 
Very few studies have shown that these cells get infected [49, 57], while various other studies 
did not detect any markers of HIV-1 infection in these cells [47, 58, 59]. Some in vitro studies 
have shown that these cells can be infected with HIV-1 [60, 61], but it is a nonproductive 
infection. 
HIV-1-mediated neurotoxicity 
Though HIV-1 induces profound changes in neuronal morphology, function and survival, the 
virus itself rarely infects neurons [22, 47, 49, 58]; instead, viral proteins directly cause neuronal 
damage or infected and/or activated glial cells produce cellular factors that drive secondary 
toxicity in neurons, known as bystander effects [22, 62-65]. 
‘Direct injury’ hypothesis suggests that HIV-1 proteins, mainly transactivator of transcription 
(Tat), gp120, negative regulatory factor (Nef) and viral protein R (Vpr), directly cause neuronal 
damage or death without requiring the intermediary functions of non-neuronal cells [22, 62, 63]. 
Various studies using primary neuron and neuroblastoma cell line cultures have shown that 
individual viral proteins induce toxicity including neurite degeneration and cell death [66-74]. 
However, in most of these studies the concentrations of viral proteins used were well above the 
levels thought to be present in brains of HIV-1-infected patients [62, 63, 75]. Thus, we need to 
be cautious when extrapolating results from these in vitro studies to actual human disease 
settings. 
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‘Indirect injury’ or ‘bystander effects’ hypothesis suggests that cellular factors including 
cytokines, chemokines, excitotoxic factors and free radicals, released from infected and/or 
activated non-neuronal cells cause neuronal toxicity [22, 62, 63]. Several studies have shown that 
infected and/or activated non-neuronal cells, mainly perivascular macrophages, microglia and 
astrocytes, release various pro-inflammatory and/or neurotoxic factors including tumor necrosis 
factor- α (TNF-α), interleukin-1β (IL-1β), IL-6, transforming growth factor-β (TGF-β) 
interferon-γ (IFN-γ), fractalkine (CX3CL1), monocyte chemotactic protein-1 (MCP-1; CCL2), 
RANTES (CCL5), matrix metalloproteinases (MMPs), arachidonic acids, glutamate, cysteine, 
quinolinic acid (QA), nitric oxide (NO), free radicals etc. [22, 62, 63, 76-84]. Virus and/or viral 
factors are also known to disturb neuron supportive functions of glia [51, 85, 86], which may 
exacerbate neuronal damage. 
As available data support the role for both, ‘direct’ and ‘indirect’ injury hypotheses, two 
hypotheses/mechanisms might coexist. But in in vivo settings where neurons are in continuous 
contact/communication with glia, the ‘indirect injury’ hypothesis seems to predominate [62, 63]. 
Synaptodendritic degenerative changes are thought to be the major substrate underlying HIV-1 
related neurocognitive impairments. At least during the early stage of disease, synaptodendritic 
changes are more predominant than cell death; in HIV-1-infected individuals the degree of 
neurocognitive deficits is closely correlated to degeneration of synaptodendritic structures [87-
91]. Initial damage at synapses and dendrites may culminate into cell death; postmortem analyses 
of brains of HIV-1-infected patients have shown evidence for neuronal death [92-95]. 
Though HIV-1 rarely, if ever, infects mature neurons, there is some evidence that neural 
progenitor cells may be permissive to infection [96]. HIV-1 and gp120 are known to decrease 
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proliferation and/or differentiation capacity of neural progenitor cells [97, 98]. It is also reported 
that number of proliferating cells in the hippocampus of HIV-1-infected patients is reduced [97]. 
Thus, it can be predicted that HIV-1 causes neurocognitive deficits not only by damaging 
existing neurons but also by impairing neurogenesis [99]. 
HAND 
HIV-1 can induce a wide range of CNS deficits, including cognitive decline, personality 
changes, motor deficits and dementia, collectively known as HIV-1-associated neurocognitive 
disorders (HAND) [100-104]. Nearly 50% of HIV-infected patients experience HAND [88, 105-
107]. Neurological impairments tend to be milder during early phase of HIV-1 infection, but 
severity of HAND upsurges with disease progression [108-110]. The occurrence and severity of 
HAND varies among HIV-infected patients; it may be because of differences in the individual’s 
genetic control of immune system [103]. There are three diagnostic terms commonly used to 
describe the severity of HAND [88, 104]: (a) asymptomatic neurocognitive impairments (ANI): 
refers to mild neurocognitive deficits, do not interfere with patients’ everyday functioning; (b) 
mild neurocognitive disorders (MND): refers to mild to moderate neurocognitive impairments, 
interfere modestly with everyday functioning of patients; (c) HIV-associated dementia (HAD): 
refers to moderate to severe neurocognitive impairments, markedly disturb patients’ day-to-day 
functioning, these patients are incapable of living independently. 
cART has markedly controlled systemic HIV-infection, and has improved the health status of a 
large segment of patients [105, 111, 112]. Although cART has reduced the overall severity of 
neurocognitive disorders in HIV-1 patients, the prevalence of HAND remains same [88, 105-
107, 111, 113]. The persistence of relatively high rates of CNS disease is likely due to a 
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combination of longer patient survival, the relatively poor CNS penetrance of most antiretroviral 
drugs [88, 114], and their neurotoxic effects [115, 116]. Inhibiting viral replication in periphery 
by cART can partially reverse neurocognitive deficits [117, 118]. However, some patients  who 
have responded positively to early cART with time have reverted back and are showing 
continued neurocognitive decline [119, 120]. In some cART receiving patients, although viral 
replication in the periphery is significantly controlled, viral loads in the CSF are unchecked, a 
phenomenon called CNS escape [121-123]. In some patients, even if the CNS viral load is 
extremely low or undetectable, neurodegeneration can still occur in response to viral proteins, 
such as Tat, that are released from cells even when viral replication has been inhibited [124]. 
HIV and Opiate Drugs of Abuse 
Illicit drug abuse is a significant risk factor for HIV-transmission due to sharing of contaminated 
needles and unsafe sexual activities. Nearly 30% of HIV-infected patients have history of drug 
abuse, which frequently include opiates [125-127]. Other than illicit drug abuse, a large subset of 
HIV
+
 patients are exposed to opiates for treatment of AIDS-related chronic pain syndromes. 
Opiates by themselves are known to affect normal immune system function, including antibody 
production, monocyte and T-cell functioning and natural killer (NK)-cells cytotoxicity [126, 
128-130]. Opiates enhance immune cell inflammation and also increase expression of cytokine 
receptors including CCR5 and CXCR4 [131-134], co-receptors for HIV-1-entry. Morphine, an 
opiate that preferentially acts through µ-opioid receptors (MORs), enhances HIV-1 
replication/expression in phytohaemagglutinin (PHA)-activated cultured human peripheral blood 
mononuclear cells (hPBMCs) [135]. Chronic morphine treatment of simian immunodeficiency 
virus (SIV)-infected rhesus macaques has shown to cause increase in viral replication, increased 
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rate of viral mutation and tolerance to azidothymidine (AZT or Zidovudine), an antiretroviral 
drug, and decrease in life span of infected animals [131, 136-138]. Thus, it is likely that opiate 
abuse not only increases risk of HIV-infection but also accelerates disease progression to clinical 
AIDS. 
Since opiate drugs of abuse themselves are known to induce neurotoxic/neuropathological 
effects, such as blood brain barrier (BBB) breakdown, immune and glial cell activation, neuronal 
damage etc. [139-144], it can be predicted that opiate drugs of abuse will exacerbate HIV-1-
associated pathogenesis in CNS. Opiates can interact directly to aggravate HIV-1-mediated 
neurodegeneration, or they can act indirectly via exacerbating HIV-1-mediated glial cell 
inflammation [125, 145-156]. Opiate drug abusing HIV
+
 patients are more susceptible to develop 
HIV encephalitis (HIVE), which may lead to HAND [157-159]. The severity of neurological 
deficits in opiate drug abusing HAND patients have been shown to be elevated compared to non-
drug abusing patients [160-162]. 
GSK3β 
Glycogen synthase kinase 3 (GSK3) was first identified as a regulator of glycogen metabolism; 
inactivating phosphorylation of glycogen synthase by GSK3 is a central regulatory process in 
glycogen biosynthesis [163-166]. GSK3 is a multifunctional serine/threonine kinase which is 
ubiquitously expressed in eukaryotes. GSK3 exists in two highly homologous isoforms, α and β. 
Both isoforms are highly conserved within their kinase domain; GSK3β is smaller, consists of 
482 amino acids, while GSK3α additionally contains glycine-rich N-terminus extension [163, 
165, 167-169]. Both isoforms are widely expressed in all tissues; however, in the brain GSK3β is 
present in high abundance. Widespread expression of GSK3β in the brain suggests that it plays a 
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vital role in various neuronal signaling pathways. GSK3β is known to be an important player in 
regulation of CNS development; it plays a critical role in neurogenesis, neuronal migration, 
neuronal polarization, and axon growth and guidance [163, 166, 167, 169-171]. 
GSK3β is a constitutively active enzyme. Various kinases are known to phosphorylate GSK3β at 
Ser-9 and thereby reduce its enzyme activity, including Akt (also known as protein kinase B; 
PKB), p90 ribosomal s6 kinase (p90
rsk
), protein kinase A (PKA; also known as cyclic AMP-
dependent protein kinase) and protein kinase C (PKC). On the contrary, phosphorylation of 
GSK3β at Tyr-216 by ZAK1 or Fyn increases its enzyme activity [163, 165, 169, 172, 173]. 
Various growth factors induce their neurotrophic effects via reducing the activity of GSK3β by 
phosphorylation at Ser-9, including fibroblast growth factor 1 (FGF1), FGF2, insulin growth 
factor 1 (IGF-1), epidermal growth factor (EGF) and platelet-derived growth factor (PDGF); 
while pro-apoptotic stimuli increase GSK3β activity via phosphorylation at Tyr-216 [163, 165, 
173, 174]. 
GSK3β plays a crucial role in regulating functioning of various structural, metabolic and 
signaling proteins in neurons including tau, MAP2, β-Catenin, activator protein 1 (AP-1), cyclic 
AMP response element binding protein (CREB), nuclear factor-kappa B (NF-κB), heat shock 
factor-1 (HSF-1) and others. These signaling proteins regulate a variety of cellular functions 
including neuronal plasticity, gene expression and cell survival [163, 165, 166, 175]. 
Dysregulated GSK3β activity appears to be operant in various neuropathological conditions, 
including Alzheimer’s disease, Parkinson’s disease, schizophrenia, autism and bipolar mood 
disorder, and pharmacological inhibition of GSK3β ameliorate these diseases [163, 169, 173, 
175-183]. 
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Role of GSK3β in HIV-1-mediated neurotoxicity 
Various studies with neurons in cultures as well as with animal models have shown that HIV-1 
induces neurotoxic effects via increase in the GSK3β activity, and the GSK3β inhibitors 
ameliorate these toxic effects [174, 184-188]. The pathways through which HIV-1 induces 
GSK3β activation are unclear. But the mechanisms through which GSK3β-activation promotes 
neuronal damage mainly include β-Catenin and tau phosphorylation [184, 185]. β-Catenin is an 
immediate downstream target of GSK3β; active GSK3β phosphorylates and thereby initiates 
rapid ubiquitin-mediated degradation of β-Catenin, which otherwise positively regulate cell 
survival and neurite outgrowth [173, 175, 189-191]. Tau-hyperphosphorylation has been 
associated with neurodegenerative disorders, including Alzheimer’s disease [192-194]. GSK3β is 
a principal tau-kinase [195-197]. Tau-hyperphosphorylation causes microtubule cytoskeleton 
destabilization, leads to neurite degeneration. In addition to β-Catenin and tau, GSK3β regulates 
the functioning/stability of various structural and signaling molecules that appears to play roles 
in cell death and neurite damage [165, 175]. 
Recent studies have identified GSK3β as a central mediator of pro-inflammatory processes in 
immune cells, including microglia [169, 198-200]. Thus, it is likely that GSK3β-activation may 
play role in HIV-1mediated immune and glial cell activation, and the release of pro-
inflammatory cytokines, leading to ‘bystander’ neuronal damage. A recent study by Kehn-Hall et 
al. has shown that 6BIOder, a novel GSK3β-inhibitor, inhibits HIV-1 replication [201], 
suggesting that GSK3β-activation may play a role in viral propagation. 
Taken together, these studies support a central role of GSK3β-activation in HIV-1-mediated 
neurotoxicity. In accord with these studies, several pilot clinical trials have demonstrated 
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improvements in neuropsychological performance in HAND patients treated with GSK3β 
inhibitors as adjunct therapy with stable cART [202-204]. Thus, it can be concluded that GSK3β-
mediated signaling pathways are potential therapeutic target in treatment of neuroAIDS. 
Role of GSK3β in opiate-mediated neurotoxicity 
Results from some previous studies have conflict regarding whether opiates induce GSK3β 
activation or inactivation; some studies have shown that opiates induce GSK3β activation [205-
207], while some have shown that they inactivate it [208, 209]. Altogether, from these studies it 
can be inferred that opiates induce dose- and time-dependent effects on GSK3β activity; acute 
activation of MORs inactivates GSK3β by inducing phosphorylation at Ser-9 via 
phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, while chronic activation of MORs 
induces GSK3β activation by inducing phosphorylation at Tyr-216, may be through elevation in 
cytosolic Ca
2+
 [205]. 
Studies from brains of opiate abusing patients suggest a role of GSK3β-mediated signaling 
pathways in opiate-associated neuropathology. The accelerated deposition of 
hyperphosphorylated tau that occurs in the CNS of young opiate abusers [141, 142] is likely 
related to elevated GSK3β expression [141] since GSK3β is a principal tau kinase [195-197]. 
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CHAPTER 2 
Morphine Enhances HIV-1SF162-Mediated Neuron Death and Delays Recovery of Injured 
Neurites 
(This chapter has been published as an article; PLoS ONE 9(6): e100196. 
doi:10.1371/journal.pone.0100196) 
Introduction 
Human immunodeficiency virus-1 (HIV-1) disrupts normal immune system function and leads to 
acquired immunodeficiency syndrome (AIDS).  HIV-1 can also induce a wide range of central 
nervous system (CNS) deficits, collectively known as HIV-1-associated neurocognitive disorders 
(HAND). HIV-1 enters the CNS soon after initial systemic infection [22, 24]. It is widely 
believed that virus penetrates the CNS within infected monocytes and lymphocytes [22, 210], 
which normally traffic across the blood-brain barrier (BBB) as a part of immune surveillance of 
the brain. Mature neurons are not infected by HIV-1; instead, infected and/or activated glial cells 
release various viral and cellular factors that induce direct and/or indirect neuronal toxicity, 
leading to HAND [22, 65, 88, 211, 212]. Combination antiretroviral therapy (cART), which 
controls systemic HIV-infection, has improved the health status of a large segment of patients 
[105, 111, 112]. Although cART has reduced the overall severity of neurocognitive disorders in 
HIV-1 patients, the prevalence of HAND remains at approximately 50% [88, 105-107, 111]. The 
persistence of relatively high rates of CNS disease is likely due to a combination of longer 
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patient survival, the relatively poor CNS penetrance of most antiretroviral drugs [88, 114], and 
their neurotoxic effects [115]. Even if the CNS viral load is extremely low or undetectable, 
neurodegeneration can still occur in response to viral proteins, such as transactivator of 
transcription (Tat), that are released from cells even when viral replication has been inhibited 
[124]. 
Injection drug abusers are at high risk of acquiring HIV-infection due to sharing of contaminated 
needles and unsafe sexual behavior. Nearly 30% of HIV-infected patients have a history of 
injection drug abuse involving opiates [125, 127]. Additionally, a subset of HIV
+ 
patients is 
exposed to opiates through their legitimate use for treatment of AIDS-related chronic pain 
syndromes. As opiates by themselves are known to induce immunomodulatory or 
immunosuppressive effects, both in the periphery and CNS [132, 140], it is hypothesized that 
they may enhance virus spread or otherwise exacerbate disease processes. Experimental evidence 
also suggests that opiates can interact with HIV-1 or HIV-1-proteins directly on CNS cells and 
tissues [125, 145, 147-151, 153]. Among patients with HIV-1 infection, those who also abuse 
opiate drugs show faster progression to AIDS and more severe neurocognitive deficits [160-
162]. 
Many previous studies have modeled HIV-neuropathology using individual viral proteins, such 
as Tat, glycoprotein 120 (gp120), and others. However, the CNS of HIV-infected patients is not 
only exposed to individual viral proteins, but instead to all cytokines/chemokines and other 
cellular products, viral proteins and virus particles released from infected and/or activated cells. 
Thus, to more closely model HIV-1-mediated neurotoxicity, we have used supernatant from 
HIV-1SF162-infected differentiated-U937 cells (HIV
+
sup). The R5-tropic HIV-1SF162 strain was 
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used since R5-tropic (monocyte/macrophage-tropic) viruses are predominant in cerebrospinal 
fluid (CSF) and CNS parenchyma [213, 214]. 
Multiple outcome measures were studied after HIV
+
sup ± morphine treatments, including both 
cell death and neurite degeneration. Studies in the presence of glia allowed us to distinguish 
between direct and indirect neurotoxicity. Our results indicate that morphine worsens selective 
neurotoxic effects of HIV, and that glycogen synthase kinase-3β (GSK3β) signaling may be a 
point of convergence. Importantly, morphine limits the ability of neurons to recover from 
sublethal damage. 
Materials and Methods 
Ethics statement 
Experiments were conducted in accordance with procedures reviewed and approved by the 
Virginia Commonwealth University Institutional Animal Care and Use Committee (Protocol 
Number: AM10158). 
Mixed glial cultures 
Cells were cultured from the striatum, a region targeted by HIV where opioid receptor levels are 
relatively high.  Mixed glial cultures (astrocytes and microglia) from mouse striatum were 
prepared as previously described [151, 153], with minor modifications. Striata from P0-P1 ICR 
(CD-1) mice (Charles River Laboratories International, Inc., Wilmington, MA) were dissected, 
minced and enzymatically dissociated with trypsin (2.5 mg/ml; Sigma-Aldrich, St. Louis, MO) 
and deoxyribonuclease (DNase; 0.015 mg/ml; Sigma-Aldrich) in Dulbecco’s Modified Eagle’s 
Medium (DMEM; Gibco, Grand Island, NY) for 30 min at 37°C. Tissue was resuspended in 
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DMEM supplemented with 10% fetal bovine serum (FBS; Gibco), triturated and filtered through 
100 and 40 μm nylon mesh pore filters respectively. Cells were plated and maintained in 
supplemented DMEM containing 10% FBS.  
Neuronal cultures 
Mouse striatal neuron cultures were prepared as previously described [151, 153]. Briefly, striata 
from E15-E16 ICR mice were dissected, minced and enzymatically dissociated with trypsin (2.5 
mg/ml) and DNase (0.015 mg/ml) in neurobasal medium (Gibco) for 30 min at 37°C. Tissue was 
resuspended in neurobasal medium supplemented with B-27 additives (Gibco), L-glutamine (0.5 
mM; Gibco) and glutamate (25 µM; Sigma-Aldrich), triturated and filtered twice through 70 µm 
nylon mesh pore filters. Neurons were plated and maintained in supplemented neurobasal 
medium. Culture purity was determined by immunocytochemistry using anti-MAP-2 antibody 
(Abcam, Cambridge, MA; ab32454) and found to be > 80% neurons.    
Neuron-mixed glial co-cultures  
All cultures were prepared in 24 well plates pre-coated with poly-L-lysine (0.5 mg/ml; Sigma-
Aldrich). Neurons were plated alone in 12 wells (neuron cultures); in the remaining 12 wells we 
established neuron-glia co-cultures as previously described [153]. Briefly, two deep midline 
grooves were made into the culture surface to restrict the movement of glial cells between sides. 
Glial cells (2×10
5
 cells/well) were plated on one side of the grooves; when they became 
confluent (10 d), neurons (0.25×10
5
 cells/well) were plated onto the entire culture surface. In 
these wells, all neurons are exposed to glial conditioned medium, but neurons on one side of the 
grooves contact the glial bedlayer, while neurons on the other side grow in isolation on the 
culture surface. It is difficult to visualize all neurite extensions when neurons are in contact with 
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the glial bedlayer. Thus, the co-culture studies used neurons that did not have direct contact with 
glia. All cultures were maintained in supplemented neurobasal medium; neurons were allowed to 
mature for 5-7 d prior to treatment.  
Supernatant from HIV-infected cells 
U937 cells (ATCC, Manassas, VA), a leukemic monocyte cell line originally derived from a 
histiocytic lymphoma, were plated at 0.5 × 10
5
 cells/ml in RPMI-1640 media (Gibco) 
supplemented with 10% FBS, and activated/differentiated with interleukin-2 (IL-2, 100 ng/ml; 
Sigma-Aldrich), phytohaemagglutinin (PHA, 5 µg/ml; Sigma-Aldrich), and phorbol 12-myristate 
13-acetate (PMA, 100 ng/ml; Sigma-Aldrich), for 48 h. Activated/differentiated cells were 
treated with Polybrene (2 μg/ml; Sigma-Aldrich) for 30 min at 37°C, resuspended in fresh 
medium and exposed to HIV-1SF162 (p24 = 50-100 pg/ml; from Dr. Jay Levy [215], through the 
NIH AIDS Research and Reference Reagent Program, Germantown, MD). After 7 d, 
supernatants were collected by filtering through a 0.20 μm filter. HIV infection was confirmed 
by quantification of p24 levels (HIV-1 p24 Antigen Capture Assay; Advanced Bioscience 
Laboratories, Rockville, MD) in culture supernatants; a 4-6 fold increase in p24 antigen levels 
was typical over 7 d. Supernatants from uninfected/untreated U937 cells (Controlsup) were used 
as a control. Cell culture supernatants were aliquoted and stored at -80°C. 
Treatments 
 Morphine is the major metabolite of heroin in the CNS [216]; it preferentially targets µ-opioid 
receptors (MORs). Since opiates by themselves can affect HIV-1 infection and replication [217], 
it was important to assess the effects of opiate interactions using cell-free supernatants. HIV
+
sup 
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or Controlsup was added to neuronal cultures in the presence or absence of morphine sulfate (500 
nM; Sigma-Aldrich) ± naloxone (1.5 µM; Sigma-Aldrich), a general opioid receptor antagonist. 
MTT assay  
At specific times after treatment, cells were rinsed and incubated with 1.2 mM 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Molecular Probes, Grand Island, 
NY) in fresh, pre-warmed media at 37°C for 4 h. The medium was gently aspirated, and 
formazan crystals, the product of reduction of MTT by mitochondrial dehydrogenase in live 
cells, were dissolved in 100 µl of dimethyl sulfoxide (DMSO; Sigma-Aldrich) at 37°C for 10 
min. The amount of formazan was measured by absorbance at 540 nm using a PHERAstar 
microplate reader (BMG LABTECH Inc., Cary, NC).  
TUNEL assay  
At specific intervals after treatments, cells were fixed overnight at 2-8°C in 4% 
paraformaldehyde (Sigma-Aldrich), permeabilized at room temperature in 0.1% Triton-X 100 
(Molecular Probes) and 0.1% BSA (Invitrogen, Grand Island, NY) for 15 min, and blocked in 
0.1% BSA and 1% horse serum for 30 min. Fixed cells were stained for Hoechst 33342 (Sigma-
Aldrich) and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL; Roche 
Applied Sciences, Mannheim, Germany). Cells were visualized and digital images were acquired 
using an Axio Observer Z.1 microscope and Zen 2010 software (Zeiss Inc., Thornwood, NY). 
Neuronal apoptosis was assessed by manually counting the percentage of TUNEL(+) cells. 
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Assessment of neuronal viability  
In each culture well, at least 50 healthy neurons were initially selected in 6-8 non-overlapping 
fields. After treatment, repeated images of pre-selected cells were captured at 1 h intervals, using 
a microscope with a computer-regulated stage (Axio Vision 4.6; Carl Zeiss Inc.) under controlled 
environmental conditions (37°C, 95% humidity and 5% CO2) [151, 153]. At the end of each 
experiment, pre-selected neurons were assessed for viability at 6 h intervals in the digital images. 
Cell death was confirmed using rigorous morphological criteria including abnormal shrinking of 
the cell body and eventual cell body fragmentation, nuclear destruction, loss of phase-brightness, 
and excessive neurite loss [151, 153, 218]. In some experiments, live and dead cells were 
confirmed at the end of the experiment by staining respectively with calcein-AM and ethidium 
homodimer-1 (LIVE/DEAD Viability/Cytotoxicity Kit; Molecular Probes, Grand Island, NY). 
Findings were reported as the average percentage of neuron survival, with respect to pre-
treatment neuron count ± standard error of the mean (SEM), and analyzed using a repeated 
measure analysis of variance (ANOVA) and Duncan’s post hoc test using Statistica 8.0 (StatSoft, 
Tulsa, OK). 
Assessment of neurite length  
At specific intervals after treatments, cells were fixed, permeabilized, blocked, and subsequently 
stained for TUNEL and MAP-2 (Abcam; ab32454); cells were visualized and digital images 
were acquired. In digital images, neuritic arborization was quantified only for live [TUNEL(-)] 
neurons, using modified Sholl analysis. A ‘Sholl score’ was measured by counting the number of 
intersections of MAP-2-positive neurites with equidistant concentric circles of increasing radius, 
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centered on the cell body [219]. The Sholl score was converted into neurite length in µm via 
micrometer calibration at the same magnification.  
Assessment of neurite growth/regrowth after treatment removal  
Prior to treatment, at least 15 healthy neurons were selected in 7-8 non-overlapping fields per 
well. Repeated images of pre-selected cells were captured at 1 h intervals after treatment onset. 
After 24 h, cells were gently rinsed with pre-warmed medium and returned either to a ‘control ± 
opiate environment’, which had Controlsup, or to a ‘HIV ± opiate environment’ which had 
HIV
+
sup (Table 1). We then continued to capture images of the same neurons at 1 h intervals for 
an additional 48 h (total 72 h). Thus, there were a total of 9 groups with varying exposure times 
to HIV
+
sup or Controlsup, in the presence or absence of morphine ± naloxone; these are outlined in 
Table 1. 
Neurons that remained alive until the experiment end (72 h) were assessed for neuritic 
arborization in images taken at 0 h, 24 h, and 72 h using Sholl analysis. The findings were 
reported as average Sholl scores at each time, normalized to pre-treatment (0 h) scores ± SEM. 
Data were analyzed using a repeated measure ANOVA and Duncan’s post hoc test using 
Statistica 8.0 (StatSoft). 
ELISA  
Conditioned medium from mixed glial cultures were collected on the schedule described in 
Table 1 and assessed for brain-derived neurotrophic factor (BDNF), glial cell-derived 
neurotrophic factor (GDNF), interleukin 6 (IL-6) and tumor necrosis factor α (TNFα) by ELISA 
according to the manufacturer’s instructions (BDNF and GDNF ELISAs: Abcam; IL-6 and 
TNFα ELISAs: R&D Systems, Minneapolis, MN). 3,3’,5,5’-tetramethylbenzidine (TMB) 
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substrate was added for color development and plates were read at 450 nm using a PHERAstar 
microplate reader immediately after terminating the reaction. Protein levels were determined 
based on a standard curve.       
Immunoblotting 
Whole cell extracts were prepared using radioimmunoprecipitation assay (RIPA) buffer (Sigma-
Aldrich) with protease and phosphatase inhibitors (cOmplete - protease inhibitor cocktail tablets, 
and PhosSTOP - phosphatase inhibitor cocktail tablets; Roche), and total protein concentrations 
were determined by bicinchoninic acid (BCA) assay (Thermo Fisher Scientific, Rockford, IL). 
Cell lysates containing equal amounts of total protein (~5-10 μg) were heated at 100º C for 5 
minutes in laemmli buffer (Sigma-Aldrich), electrophoretically separated on a 10% SDS-
polyacrylamide gels (Criterion
 
Precast Gel; Bio-Rad, Hercules, CA), and transferred onto 
polyvinylidene difluoride (PVDF) membranes (Immun-Blot; Bio-Rad). Membranes were 
incubated with primary antibodies for phospho-GSK3β-Ser9 (p-GSK3β-S9; Cell Signaling 
Technology, Danvers, MA; 5558), GSK3β (t-GSK3β; Cell Signaling Technology; 9832) and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Abcam; ab8245). Appropriate horseradish 
peroxidase-conjugated secondary antibodies (SouthernBiotech, Birmingham, AL) were used. 
Membranes were detected using SuperSignal West Femto Maximum Sensitivity Substrate 
(Thermo Fisher Scientific), and visualized using a Kodak Image Station 440CF. 
 Statistical Analyses 
All data were expressed as average ± SEM. Unless otherwise indicated, data were analyzed 
statistically using a one-way ANOVA followed by Duncan’s post hoc test using Statistica 8.0 
(StatSoft); an α level of p < 0.05 was considered significant. 
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Results 
Dose dependent neuron death and interactions with morphine 
To determine the HIV
+
sup concentration for subsequent experiments we assessed concentration-
dependent toxicity in the presence or absence of 500 nM morphine, a titer chosen to maximally 
stimulate neuronal and glial MORs in vitro, and to result in dynamic Ca
2+
 changes and secretion 
of multiple cytokines and chemokines [145-147, 149, 151, 153, 220, 221]. HIV
+
sup at p24 ≥ 25 
pg/ml and above showed significant toxicity even in the absence of morphine in an MTT assay. 
As expected, there was a concentration-dependent decrease in MTT reduction, indicating lower 
mitochondrial activity at higher HIV
+
sup levels. At p24 concentrations ≤ 10 pg/ml, HIV
+
sup did 
not affect the MTT assay unless cells were co-exposed to morphine, indicating a significant 
synergistic effect (Fig. 2.1). At p24 concentrations ≥ 25 pg/ml, there were no significant 
interactions of HIV
+
sup with morphine. The MTT assay is a measure of the activity of NADH and 
NADPH-dependent cellular oxidoreductase enzymes [222-224]. Although it is frequently used as 
an indicator of cell survival/toxicity or proliferation, it is only an indirect measure. Therefore, 
neuron survival was directly assayed using time-lapse imaging (Fig. 2.2). Like the MTT assay, 
time-lapse image analysis showed a p24 concentration-dependent decrease in neuron survival 
over a 48 h period (Fig. 2.2B). In contrast to the MTT assay, time-lapse image analysis also 
revealed interactive effects between HIV
+
sup and morphine on cell death at p24 concentrations of 
10 and 25 pg/ml. As a p24 concentration of 25 pg/ml caused significant death/toxicity and also 
showed interactive effects with morphine, this titer was used in all further experiments. 
Importantly, 25 pg/ml falls within the range of p24 levels detected in the CSF of HAND patients 
on antiretroviral therapy (p24 = 43.2 ± 16.8 pg/ml) [225]. 
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Toxic effects of HIV ± morphine in neuron cultures 
Neuronal apoptosis was assessed using TUNEL staining (Fig. 2.3); all HIV
+
sup treatment groups 
showed significantly enhanced neuronal apoptosis at all assessed time-points (Fig. 3B; Neuron 
panel). At all time-points, except 12 h, morphine significantly enhanced HIV
+
sup-mediated 
neuronal apoptosis and the interactive effects of morphine were blocked by naloxone. TUNEL 
staining is specific for death involving apoptotic pathways, and may not detect all dying neurons. 
Additionally, TUNEL does not distinguish and permit the exclusion of cells that were dead at the 
start of the treatment. Time-lapse imaging was used to more exactly follow cell survival/death 
(Fig. 2.4). Over the period of 72 h, HIV
+
sup ± morphine treatments significantly reduced neuronal 
survival in cultures without glia (Fig. 4; Neuron panel). Morphine significantly enhanced 
neuronal death mediated by HIV
+
sup, and interactive effects of morphine were blocked by 
naloxone.  
Sublethal synaptic losses and neuritic pruning are thought to be a major substrate of 
neurocognitive disorders [87-91]. Therefore, effects of HIV
+
sup ± morphine treatment on neuritic 
arborization were assessed using MAP-2-immunostaining followed by modified Sholl analysis 
(Fig. 2.5); only those neurons determined to be alive by TUNEL assay were used in the analysis. 
At all assessed time-points, HIV
+
sup ± morphine treatment groups showed significantly reduced 
neurite length (Fig. 2.5B; Neuron panel). Morphine did not show a significant interaction with 
HIV
+
sup at any time. 
Role of glia in HIV ± morphine-mediated neurotoxicity 
HIV does not infect mature neurons; instead, virotoxins can cause indirect neuron damage via 
inducing an inflammatory response in activated and/or infected glia [22, 65, 88, 211, 212]. To 
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determine the role of glia in HIV
+
sup ± morphine-mediated neurotoxicity, treatments were carried 
out either in the presence or absence of glia. The presence of glia significantly increased the 
proportion of HIV
+
sup ± morphine-induced TUNEL(+) neurons (Fig. 2.3B; compare panels). At 
the earliest time point examined (12 h), HIV
+
sup and morphine displayed a significant interaction; 
however this only occurred in the presence of glia. Thus, glia appeared to accelerate the HIV
+
sup-
morphine interaction. At all time points except 72 h, the interactive effects of morphine were 
significantly attenuated by naloxone. Chronic exposure to naloxone is occasionally ineffective, 
even when acute blockade reverses morphine effects [226]. This may be due to blocking the 
cellular effects of the multiple opioids normally released by glia [227, 228]. The presence of glia 
significantly enhanced HIV
+
sup  ± morphine-mediated neuron death over the entire 72 h 
experimental period (Fig. 2.4; compare panels). 
In the subpopulation of neurons that survived, HIV
+
sup induced significant neurite pruning or 
growth arrest. The presence of glia did not significantly affect HIV
+
sup-induced neurite pruning, 
even when neurons were co-exposed to morphine. In fact, in the presence of glia, Controlsup-
treated groups had significantly longer neurites (Fig. 2.5B; compare panels). 
Reversibility of HIV ± morphine-mediated neurite damage 
Neurons appear to recover from certain types of sublethal damage caused by HIV-related insults 
[87, 88, 90]. Therefore, the reversibility of HIV- and morphine-mediated neurite damage was 
tested. HIV
+
sup ± morphine treatments caused significant neurite growth arrest over the period of 
24 h in cultures without glia (Fig. 2.6B; Neuron panel). With continuous exposure to HIV
+
sup ± 
morphine for 72 h, neurite length remained significantly reduced. When HIV
+
sup was removed at 
24 h, neurites resumed their growth. Interestingly, sustained exposure to morphine by itself was 
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sufficient to reduce and/or delay neurite recovery/outgrowth despite the removal of HIV
+
sup. This 
effect of morphine was blocked by naloxone. 
Since glia support neurite outgrowth and synapse remodeling through multiple mechanisms 
[229-232] we tested whether glia play a role in the reversibility of HIV- and morphine-mediated 
neurite pruning/growth arrest. As in the neuron-only cultures, HIV
+
sup ± morphine treatments 
caused significant neurite growth arrest over 24 h when glia were present (Fig. 2.6B; Neuron-glia 
panel). In the presence of glia, neurite outgrowth was significantly faster after removal of 
HIV
+
sup than it was in neuron-only cultures (Fig. 2.6B; compare panels). 
HIV- and morphine-mediated effects on secretion of growth factors and cytokines by glia 
Our results show that glial effects on neuron injury and recovery are dependent on the context of 
HIV and morphine. Glia enhanced HIV-driven neuronal death (Fig. 2.3B and 2.4), but 
accelerated neurite recovery after removal of HIV (Fig. 2.6B). To determine how glia might 
direct these outcomes, we examined whether HIV and morphine affect glial production of 
secreted factors known to influence neuronal survival and outgrowth. ELISA was used to assay 
levels of the neurotrophic factors (BDNF and GDNF), as well as cytokines (IL-6 and TNFα) that 
indicate glial inflammatory activation (Fig. 2.7); they showed multiple response patterns. BDNF 
levels were significantly reduced by HIV
+
sup ± morphine treatments. BDNF recovered to control 
levels after removal of HIV
+
sup, even though morphine remained present. GDNF levels were 
unaffected by any treatment. IL-6 levels were increased by HIV
+
sup or morphine treatment alone, 
and in addition, morphine significantly augmented the effect of HIV
+
sup. Although IL-6 levels 
returned to control after removal of HIV
+
sup, the elevated levels were maintained in the continued 
presence of morphine. TNFα release was significantly increased by HIV+sup alone, but not by 
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morphine alone, although morphine co-treatment augmented the effect of HIV
+
sup. TNFα levels 
returned to control after removal of HIV
+
sup, even in the continuous presence of morphine. Thus, 
among the secreted factors whose levels were influenced by HIV and morphine, BDNF, TNFα 
and IL-6 responded to HIV
+
sup alone, while only IL-6 was affected by morphine itself. Both 
TNFα and IL-6 showed HIV-morphine interactive effects. Only IL-6 continued to respond to 
morphine exposure after HIV removal. 
GSK3β as a point of convergence for HIV and morphine 
Previous studies have shown that HIV-1 induces neurotoxic effects by enhanced activation of 
GSK3β [174, 184-188], and that GSK3β is also linked to neuropathology seen with opiate-
abusing patients [141, 142]. We therefore tested whether GSK3β might be a site of HIV and 
morphine interactions. Neurons grown in isolation were lysed at 24 h after treatments with 
HIV
+
sup ± morphine and immunoblotted for phospho-GSK3β-Ser9 (p-GSK3β-S9; an inactive 
form of GSK3β [165, 173, 175, 233]), GSK3β (total GSK3β; t-GSK3β) and GAPDH (Fig. 2.8). 
HIV
+
sup and morphine by themselves induced significant reduction in p-GSK3β-S9 with respect 
to t- GSK3β. Morphine co-treatment significantly augmented HIV+sup-mediated effects. All of 
the effects of morphine were blocked by naloxone. 
Discussion 
Our studies conclusively show that opiates can directly exacerbate the deleterious effects of 
HIV-1 on neurons in an infective model in vitro, although past studies have demonstrated that 
morphine interacts with the HIV-1 proteins Tat [149, 153] and gp120 [151]. The present studies 
also confirm and extend prior findings of glial involvement in interactions between opiates and 
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HIV proteins, demonstrating that combined morphine and HIV-1SF162 neurotoxicity can be 
amplified in the presence of glia. Lastly, we found that continuous morphine exposure 
significantly restricted the ability of neurons to recover from exposure to HIV
+
sup. This suggests 
that HIV-opiate co-exposure may trigger maladaptive cellular responses that persist in the 
presence of opiates alone, even after HIV infection is mitigated. Importantly, this situation is 
relevant to opiate-exposed patients whose HIV infection is controlled with cART. 
Experimental models for HIV ± opiate-mediated neurotoxicity 
 Since HIV is a human-specific disease, models in other species have deficiencies as well as 
strengths. For example, non-human primates have been an invaluable model to assess interactive 
effects of the HIV-like simian immunodeficiency virus (SIV) and opiates [234, 235]. However, 
limited availability and the lack of established simian culture models make mechanistic studies 
difficult.  There are rodent in vivo models that closely mimic viral infection, including an HIV-1 
transgenic rat that expresses a majority of HIV-1 proteins without viral replication [236], and 
“humanized” SCID mice in which establishment of a human immune system in mice permits 
HIV infection [237]. However, in both cases the peripheral and central target cells are those of 
the rodent host.  Our past in vivo studies have used a Tat transgenic mouse in which Tat 
production is largely restricted to the CNS [145, 148], and we have also examined effects of 
HIV-1 proteins on murine cells in vitro [149, 151-153, 218, 238]. In general, the findings in 
culture have paralleled outcomes in vivo; all have closely modeled key aspects of 
neurodegeneration and inflammatory biomarker production seen clinically in the CNS. We are 
specifically interested in effects on striatal neurons, since the striatum is a major target of HIV-1, 
and since levels of opioid receptors in the striatum are relatively high [149, 239, 240]. Although 
primary human cells may be preferable as an in vitro model, we have used murine targets since 
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human neurons/glia from specific brain regions are not consistently available, and outcomes 
frequently show regional specificity [241, 242]. Additionally, murine cultures (a) eliminate 
human genetic variability in terms of MOR [243], CCR5 [244, 245], and other factors that 
influence infective and neurodegenerative processes; and, (b) are free from any confounding 
effects of morphine on HIV replication in human microglia [217]. Still, the issue of species 
mixing must be considered when interpreting results in this model. 
Neurotoxicity induced by HIV ± morphine 
The extent to which opiates contribute to the progression of HAND in the era of cART remains 
controversial, although some large clinical studies now support moderate interactive effects [160, 
161]. Opiate drugs of abuse have been shown to enhance particular damaging effects of HIV-1 
proteins in vitro [149-153]. However, the CNS of HIV-1-infected patients is exposed to a great 
many other cellular and viral factors released from infected and/or activated cells. Current 
studies therefore used supernatant from HIV-infected cells to more fully represent the variety of 
those toxic and protective elements. HIV
+
sup caused neuronal death in a concentration-dependent 
manner over a range of p24 levels (10-500 pg/ml, Fig. 2.1 and 2.2), but significant morphine 
interactions were observed only at lower p24 levels (10 and 25 pg/ml). Very high levels of 
neuronal death at p24 ≥ 100 pg/ml may have masked interactive effects. If, as our data suggest, 
HIV-1-opiate interactions are partly governed by the level of infection, HIV-1 patients receiving 
cART may be especially vulnerable to opiate interactions since cART has greatly reduced the 
viral load [105, 111, 112]. The sensitivity of HIV-opiate interactions to levels of infection may 
also explain some controversy concerning the role of opiates in severity of HAND. 
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Since synaptic losses and neuritic pruning/degeneration are thought to be the principal substrate 
underlying HAND [87-91], we also examined length of neurites in cells that survived treatments. 
Our results show that HIV
+
sup reduced the length of neurites, but unlike the cell death results, 
there were no significant morphine interactions (Fig. 2.5). Since HIV
+
sup and morphine can 
induce multiple pathways, it is easily envisioned that interactions may differ between outcome 
measures. In some instances, cumulative reductions in synapses and dendritic simplification may 
culminate in cell death. Alternatively, neurite pruning may result in significant loss of cellular 
functions, but neurons may remain alive [238, 246]. Control treated groups actually showed an 
increase in the length of neurites over the same timeframe. This suggests that neurite length 
changes mainly reflected neurite growth arrest/inhibition. Results from repeated neurite length 
assessments of individual cells (Fig. 2.6) support this hypothesis. These conclusions are in 
conflict with some previous studies [152, 238, 247], where reduction in neurite length was 
mainly attributed to pruning of existing neurites. Disparate findings may reflect different types of 
neurons, their age and relative maturity, the response of neurons to individual viral proteins 
versus the multiple stimuli in HIV
+
sup, and the selection criteria for neurons; we specifically 
evaluated sub-lethal neurite length changes by assessing only [TUNEL(-)] cells instead of the 
entire population. 
Although many experimental and epidemiological studies have indicated a link between opiate 
drug exposure and HAND severity, the mechanisms underlying interactions between HIV-1 and 
opiates remain largely obscure. HIV-1 is known to induce neurotoxic effects through abnormal 
activation of GSK3β, and the GSK3β inhibitors, lithium (Li) and valproic acid (VPA), 
ameliorate HIV-1-mediated neurotoxicity [174, 184-188]. GSK3β signaling is also implicated in 
neuropathologic responses to opiates. For example, the accelerated deposition of 
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hyperphosphorylated tau that occurs in the CNS of young opiate abusers [141, 142] may be 
related to elevated GSK3β expression seen in opiate abusers [141] since GSK3β is a principal tau 
kinase [195-197]. GSK3β plays a crucial role in regulating the levels and function of various 
structural and signaling proteins in neurons including tau, MAP2, β-catenin, activator protein 1 
(AP-1), cyclic AMP response element binding protein (CREB), heat shock factor-1 (HSF-1), and 
among others, all of which regulate neuronal plasticity, gene expression and survival [165, 166, 
175]. GSK3β is thus well-positioned to be a potential convergence point for interactions between 
HIV-1 and opiates that regulate neuronal damage. Our results show that morphine co-exposure 
significantly augments HIV
+
sup-mediated GSK3β-activation (Fig. 2.8), supporting this 
hypothesis. 
Role of glia in HIV ± morphine-mediated neurotoxicity 
Opiates exacerbate the release of numerous factors with neurotoxic potential from glia exposed 
to HIV [125, 147, 155], and alone or in concert with HIV can disrupt certain neuron-supportive 
functions of glia, including glutamate buffering, free radical scavenging, phagocytosis and 
release of neurotrophic factors [153, 155, 248, 249]. It is easily appreciated that glia might play a 
crucial role in HIV-opiate interactions; in our previous studies glia were actually required for 
interactive neurotoxicity between morphine and HIV-1 Tat [153].  In the present study, morphine 
significantly enhanced HIV
+
sup-mediated striatal neuron death even in the absence of glia. One 
obvious interpretation is that morphine interacts with factors in addition to HIV-1 Tat in the 
HIV
+
sup. Even among R5 strains, unique gp120 sequences may result in a different degree of 
interaction between opiates and HIV [151]. While glia are clearly important determinants of 
neurotoxic HIV-opiate interactions, some interactions, perhaps those involving factors other than 
Tat, seem to occur directly upon neurons. 
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Glia also modified neurite recovery, enhancing outgrowth when HIV was removed. The effect of 
glia on neurons is never entirely positive or negative but instead reflects the net input of various 
effectors that either promote or damage neurite/neuron structure and function [229-232]. In this 
context, our finding that glial production of BDNF is suppressed by HIV
+
sup but then rebounds to 
control levels after removal of HIV
+
sup shows a return towards a more trophic glial function.  The 
normalization of proinflammatory cytokines TNFα and IL-6 after HIV removal indicates a 
similar trend, although note that continued exposure to morphine partly abrogates the effect of 
removing HIV (Fig. 2.7). 
Overall, our results show that cellular and viral products released from HIV-1SF162-infected 
leukemic monocytes have significant negative consequences on striatal neurons. Coincident 
exposure to morphine worsens neuronal outcomes in a concentration- and time-dependent 
manner. This is especially true when glia are present, although the net effects of glial exposure 
depend upon the local levels of virus and opiates. At lower viral titers, HIV
+
sup has sublethal 
effects on growth of neurite arbors, indicating that neurons may undergo functional changes long 
before they die. This may be quite relevant to the situation in HIV-infected patients where 
dendritic/synaptic plasticity, not neuron death, is the presumed substrate of HAND. Diminished 
infection levels in the CNS are probably critical in reversing HIV-driven neurite damage, 
although our results caution that chronic exposure to opiates may inflict damage even in the 
absence of HIV. 
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Tables 
Treatment Groups Treatment from 0 to 24 h Treatment from 24 to 72 h 
72h (C) Control Control 
72h (C + M) Control + Mor Control + Mor 
72h (C + M + N) Control + Mor + Nal Control + Mor + Nal 
72h (H) HIV HIV 
72h (H + M) HIV + Mor HIV + Mor 
72h (H + M + N) HIV + Mor + Nal HIV + Mor + Nal 
24h (H) then 48h (C) HIV Control 
24h (H + M) them 48h (C + M) HIV + Mor Control + Mor 
24h (H + M + N) then 48h (C + M + N) HIV + Mor + Nal Control + Mor + Nal 
 
Table 2.1: Treatment paradigm for neurite growth/regrowth assessments. Control = 
Controlsup; HIV = HIV
+
sup (p24 = 25 pg/ml); Mor = morphine sulfate (500 nM); Nal = naloxone 
(1.5 μM). 
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Figures 
 
Figure 2.1: Concentration-dependent change in MTT reduction.  Cell toxicity/proliferation 
was analyzed in neuron cultures at 48 h after treatment using an MTT assay. The findings were 
reported as percent of control absorbance at 540 nm (A540) ± SEM. Significance was analyzed 
using a one-way ANOVA and Duncan’s post hoc test, from n = 3 separate experiments. All 
treatment groups, except morphine alone [Control + Mor] and p24 = 10 pg/ml of HIV
+
sup 
[HIV(10)], showed significantly decreased absorbance at 540 nm (*p < 0.05 vs. Control), likely 
reflecting neurotoxicity. HIV
+
sup caused a concentration-dependent reduction in A540 (
$
p < 0.05). 
Morphine did not show a significant interaction with HIV
+
sup at any p24 level. Control = 
Controlsup; HIV = HIV
+
sup (concentration of p24 in pg/ml is specified in parentheses); Mor = 
morphine sulfate (500 nM). 
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Figure 2.2: Concentration-dependent neuronal death in cultures treated with HIV
+
sup ± 
morphine.  Individual striatal neurons were selected prior to treatment and repeatedly imaged 
for 48 h after treatment. (A) Digital images of the same cells/fields, at 0 h, 24 h and 48 h after 
treatment (white arrowheads indicate cells that have died over the previous 24 h period). Live 
 
 
35 
 
and dead cells were confirmed at the end of the experiment by staining respectively with calcein-
AM (green) and ethidium homodimer-1 (red); scale bar = 40 µm. (B) Cells were assessed for 
viability at 6 h intervals in digital images. Findings were reported as the average neuronal 
survival as a percent of pre-treatment neuron count ± SEM. Significance was analyzed by 
repeated measures ANOVA and Duncan’s post hoc test, from n = 3 separate experiments (at 
least 150 neurons per treatment group). Over the period of 48 h, all treatment groups except 
morphine alone [Control + Mor] and p24 = 10 pg/ml of HIV
+
sup alone [HIV(10)], showed 
significantly reduced neuronal survival (*p < 0.05 vs. Control). Neuronal survival declined in a 
concentration dependent manner with HIV
+
sup treatment (
$
p < 0.05). Morphine showed 
significant interaction with HIV
+
sup, but only at lower levels of exposure (p24 = 10 and 25 pg/ml) 
(
#
p < 0.05 vs. HIV
+
sup alone at corresponding titer). Control = Controlsup; HIV = HIV
+
sup 
(concentration of p24 in pg/ml is specified in parentheses); Mor = morphine sulfate (500 nM). 
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Figure 2.3: Neuronal apoptosis induced by HIV
+
sup ± morphine. Cells were fixed at specific 
intervals after treatment and labeled for Hoechst 33342 (blue) and TUNEL (red). (A) Digital 
images of neuronal cultures at 72 h after treatment; scale bar = 40 µm. (B) Apoptosis was 
assessed by manually counting the percentage of TUNEL(+) cells. Findings were reported as the 
average percentage of TUNEL(+) cells ± SEM. Significance was analyzed by one-way ANOVA 
and Duncan’s post hoc test, from n = 4 separate experiments. At all assessed time points, in both 
culture systems, all groups exposed to HIV
+
sup showed significantly enhanced neuronal apoptosis 
(*p < 0.05 vs. respective C group). In all cases, except at 12 h in cultures with neurons alone, 
morphine significantly augmented HIV
+
sup-mediated neuronal apoptosis (
#
p < 0.05 vs. respective 
H group). In all cases, except for 72 h in neuron-glia cultures, the interactive effects of morphine 
were significantly attenuated by naloxone. In most cases, the presence of glia significantly 
enhanced HIV
+
sup ± morphine-mediated neuron apoptosis (
$
p < 0.05 vs. corresponding treatment 
 
 
37 
 
in neuron cultures; compare panels). C = Controlsup; H = HIV
+
sup (p24 = 25 pg/ml); M = 
morphine sulfate (500 nM); N = naloxone (1.5 µM). 
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Figure 2.4: HIV
+
sup ± morphine-mediated neuronal death.  Neurons were repeatedly imaged 
for 72 h after treatment. Cells were assessed for viability at 6 h intervals in digital images. The 
findings were reported as the average percentage of neuron survival with respect to pre-treatment 
neuron count ± SEM. Significance was analyzed by repeated measures ANOVA and Duncan’s 
post hoc test, from n = 6 separate experiments. Over the period of 72 h, in both culture systems, 
all groups exposed to HIV
+
sup showed significantly reduced neuronal survival (*p < 0.05 vs. C). 
Morphine significantly enhanced HIV
+
sup-mediated neuronal death (
#
p < 0.05 vs. H), and the 
interactive effects of morphine were blocked by naloxone. In the presence of glia, HIV
+
sup ± 
morphine-mediated neuronal death was significantly enhanced (
$
p < 0.05 vs. corresponding 
treatment in neuronal cultures; compare panels). C = Controlsup; H = HIV
+
sup (p24 = 25 pg/ml); 
M = morphine sulfate (500 nM); N = naloxone (1.5 µM). 
 
 
 
 
 
39 
 
 
Figure 2.5: HIV
+
sup ± morphine-mediated neurite damage. Cells were fixed at specific 
intervals after treatment and labeled for MAP-2 (green) and TUNEL (red).  (A) Digital images of 
neuronal cultures at 72 h after treatment; scale bar = 40 µm. (B) The ‘Sholl score’ was assessed 
only for TUNEL(-) neurons in the digital images and converted into neurite length in µm via a 
micrometer-scale calibration. The findings were reported as average total neurite length per 
neuron (µm) ± SEM. Significance was analyzed by one-way ANOVA and Duncan’s post hoc 
test from n = 4 separate experiments. At all time-points and in both culture systems, all groups 
exposed to HIV
+
sup showed significantly reduced neurite length (*p < 0.05 vs. C). Morphine did 
not show a significant interaction with HIV
+
sup treatment. The presence of glia did not have a 
significant effect on HIV
+
sup ± morphine-mediated neurite damage, but in the presence of glia, 
Controlsup-treated groups showed significantly longer neurite length (
$
p < 0.05 vs. corresponding 
treatment in neuron cultures; compare panels). C = Controlsup; H = HIV
+
sup (p24 = 25 pg/ml); M 
= morphine sulfate (500 nM); N = naloxone (1.5 µM). 
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Figure 2.6: Reversibility of HIV
+
sup ± morphine-mediated neurite damage. Images of pre-
selected neurons were captured for 24 h after initial treatments, and for an additional 48 h after 
treatments were changed as described in Table 1. (A) Digital images of neuronal cultures after 
specified time and treatments (white arrowheads indicate area of neurite outgrowth since 
previous image); scale bar = 40 µm. (B) Neurons that remained alive until the experiment end 
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(72 h) were assessed for their arborization in images taken at 0, 24 and 72 h, using Sholl 
analysis. The findings were reported as average Sholl scores at each time, normalized to pre-
treatment (0 h) scores ± SEM. Significance was analyzed by repeated measures ANOVA and 
Duncan’s post hoc test, from n = 45-60 neurons per treatment group (sampled from 3 separate 
experiments; at least 15 neurons per group per experiment). Over the period of 24 h, and in both 
culture systems, HIV
+
sup ± morphine treatments induced neurite growth arrest; in neuron-glia co-
cultures, HIV
+
sup + morphine treatment appeared to cause neurite pruning (*p < 0.05 vs. 0 h, for 
corresponding treatment). After removing HIV
+
sup at 24 h, neurite growth arrest was reversible 
(
$
p < 0.05 vs. 24 h, for corresponding treatment); however, if HIV
+
sup ± morphine treatments 
were continued for 72 h, then neurite growth arrest was persisted. If morphine treatment 
continued after the removal of HIV
+
sup, neurite outgrowth was significantly reduced/delayed 
compared to neurons returned to Controlsup (
#
p < 0.05 vs. ‘24 h (H) then 48 h (C)’). This effect of 
morphine was blocked by naloxone. In the presence of glia, neurite outgrowth after removal of 
HIV
+
sup was significantly enhanced, even in the continued presence of morphine (
§
p < 0.05 vs. 
corresponding treatment and time point in neuronal cultures; compare panels). C = Controlsup; H 
= HIV
+
sup (p24 = 25 pg/ml); M = morphine sulfate (500 nM); N = naloxone (1.5 µM). 
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Figure 2.7: HIV
+
sup ± morphine-mediated effects on secretion of growth factors and 
cytokines by glia. After specified times and treatments, conditioned medium from mixed glial 
cultures was collected and assessed for levels of BDNF, GDNF, IL-6 and TNFα by ELISA; 
Growth factor / cytokine levels were determined based on a standard curve. The findings were 
reported as average concentrations (pg/ml) ± SEM. Significance was analyzed using a one-way 
ANOVA and Duncan’s post hoc test, from n = 3 separate experiments. BDNF: HIV+sup ± 
morphine treatments significantly reduced levels of BDNF (*p < 0.05 vs. ‘72 h (C)’); after 
removal of HIV
+
sup, BDNF returned to control levels (
$
p < 0.05). GDNF: HIV
+
sup ± morphine 
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treatments did not have significant effects on GDNF levels. IL-6: HIV
+
sup treatment significantly 
enhanced levels of IL-6; morphine treatment alone also significantly elevated IL-6 levels (*p < 
0.05 vs. ‘72 h (C)’), and morphine co-treatment significantly augmented HIV+sup-mediated 
effects (
#
p < 0.05). After removal of HIV
+
sup, IL-6 returned to control levels (
$
p < 0.05); in the 
continuous presence of morphine, IL-6 remained at a significantly higher level than control (*p < 
0.05) and [24h (H) then 48h (C)]-treatment group (
#
p < 0.05). TNFα: HIV+sup treatment 
significantly enhanced levels of TNFα (*p < 0.05 vs. ‘72 h (C)’); morphine co-treatment 
significantly enhanced the HIV
+
sup-mediated effect (
#
p < 0.05). After removal of HIV
+
sup, TNFα 
levels returned to control values (
$
p < 0.05). C = Controlsup; H = HIV
+
sup (p24 = 25 pg/ml); M = 
morphine sulfate (500 nM). 
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Figure 2.8: HIV
+
sup ± morphine-mediated GSK3β activation. Cells were lysed and 
immunoblotted for p-GSKβ-S9 (an inactive form of GSKβ), t- GSKβ (total GSKβ) and GAPDH 
in neuronal cultures at 24 h after treatment. Findings were reported as a percent of control values 
of p-GSKβ-S9 levels normalized with t-GSKβ (p-GSKβ-S9/t-GSKβ) ± SEM. Significance was 
analyzed using a one-way ANOVA and Duncan’s post hoc test, from n = 3 separate experiments. 
HIV
+
sup caused significant loss of p-GSKβ-S9 (*p < 0.05 vs. C). Treatment with morphine alone 
also caused significant loss of p-GSKβ-S9, and morphine co-treatment significantly augmented 
the HIV
+
sup-mediated effect (
#
p < 0.05). The effects of morphine were blocked by naloxone. C = 
Controlsup; H = HIV
+
sup (p24 = 25 pg/ml); M = morphine sulfate (500 nM); N = naloxone (1.5 
μM). 
 
 
 
 
 
45 
 
 
 
CHAPTER 3 
Comparison of HIV-1LAI and HIV-1SF162-Mediated Neurotoxicity and Interactions with 
Opiates 
(This chapter is in preparation to submit for publication) 
Introduction 
Nearly half of the human immunodeficiency virus-1 (HIV-1)-infected individuals suffer from a 
wide range of neurological disorders, including motor disturbances, dementia and behavioral 
changes, collectively known as HIV-1-associated neurocognitive disorders (HAND) [100-103]. 
HIV-1 enters the brain parenchyma soon after initial systemic infection [22-24, 250]. HIV-1 
itself rarely infects neurons [22, 47, 49, 58]; instead, infected and/or activated glial cells produce 
pro-inflammatory cytokines/chemokines and other cellular factors that, in conjunction with 
secreted viral proteins, induce ‘bystander’ damage to neurons and other cells in the CNS [22, 62-
65, 251-253]. Though combination antiretroviral therapy (cART) has significantly improved the 
health status of a large number of AIDS patients, it has not been proved equally effective for 
HAND [88, 105-107, 111, 113, 254]. This high incidence of HAND despite cART may be due to 
the longer survival of AIDS patients with milder neurocognitive disorders or result from limited 
penetration of available anti-retroviral drugs across blood-brain barrier (BBB) [88, 112, 114], or 
may be because of both.    
 
 
46 
 
Nearly one third of HIV-infected patients have a history of drug abuse, commonly involving 
opiates [125-127]. Because of sharing of contaminated needles and unsafe sexual activities, drug 
abuse is a major risk factor for HIV-transmission. Since opiate drugs of abuse induce 
immunosuppressive/immunomodulatory effects [132, 140, 255], they not only increase the risk 
of HIV-infection but also exacerbate viral spread and disease progression. As opiate drugs of 
abuse themselves induce neurotoxic effects, such as BBB breakdown, glial cell activation, and 
neuronal injury [139, 140, 154, 158], it can be predicted that  they may exacerbate HIV-1 
pathogenesis in the CNS and the severity of HAND. Many previous studies have shown that 
opiates interact with and exacerbate HIV-1-mediated neurotoxic effects [125, 145, 148-153, 
256]. This mimics more severe neurocognitive deficits observed in opiate drug abusing HIV
+
 
patients [160-162]. 
Although many studies have indicated the link between opiate drug abuse and HAND 
progression, the extent to which opiates exacerbate neurocognitive deficits is still controversial 
[257-260]. In current studies, we tried to determine whether morphine, the major active narcotic 
metabolite of injected heroin [216], exacerbate HIV-1-mediated striatal neuron toxicity; we 
tested our hypothesis using striatal cell cultures because the striatum is a principal target of HIV-
1 in the CNS and  expresses high levels of opioid receptors [239, 240, 261, 262]. 
During initial stages of HIV-infection, R5-tropic strains predominate.  However, during course 
of infection, the virus goes under evolution, in later stages of disease X4-tropic strains are more 
predominant. The co-receptor usage switch from CCR5 to CXCR4 is crucial in disease 
progression to AIDS [263-267]. Some previous studies have shown that drugs of abuse interact 
with virus or viral proteins in a strain/tropism-dependent manner [151, 268]. Our previous 
studies have shown that certain neurotoxic effects induced by HIV-1SF162, a R5-tropic strain, are 
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significantly enhanced by co-exposure to morphine [256]. The main aim of current work is to 
determine whether HIV-1LAI, a X4-tropic strain induces similar neurotoxic effects and has 
similar interactions with opiates, or whether induces differential effects in strain-dependent 
manner.  
Neurotoxic outcome measures were studied after treatments either with supernatant from HIV-1-
infected cells (HIV
+
sup) or with purified virions (HIVvirion), in the presence or absence of 
morphine. Surprisingly, we found very little differences in X4 versus R5-tropic HIV
+
sup mediated 
neurotoxicity and interactions with opiates. Interestingly, without intermediate effects of glia, 
purified virions did not induce significant neurotoxic effects and also did not cause significant 
interactions with morphine. Suggesting that HIV
+
sup mediated neurotoxic effects and interactions 
with opiates are mainly due to cytotoxic/inflammatory milieu instead of virion itself.  
Materials and Methods 
Experiments were conducted in accordance with procedures reviewed and approved by the 
Virginia Commonwealth University Institutional Animal Care and Use Committee. 
Mixed glia cultures 
Mouse striatal mixed glia (astrocytes and microglia) cultures were prepared as previously 
described [151, 153, 256]. Briefly, striata from P0-P1 ICR (CD-1) mice (Charles River 
Laboratories International, Inc., Wilmington, MA) were dissected, minced, and incubated with 
trypsin (2.5 mg/ml; Sigma-Aldrich, St. Louis, MO) and deoxyribonuclease (DNase; 0.015 
mg/ml; Sigma-Aldrich) in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco, Grand Island, 
NY) for 30 min at 37°C. Tissue was resuspended in DMEM supplemented with 10% fetal bovine 
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serum (FBS; Gibco), triturated, and filtered through 100 and 40 μm pore nylon mesh filters. 
Cells were plated and maintained in DMEM supplemented with 10% FBS. 
Neuron cultures 
Neuron cultures from E15-E16 ICR (CD-1) mouse striatum were prepared as previously 
described [151, 153, 256]. Striata were dissected, minced, and enzymatically dissociated with 
trypsin (2.5 mg/ml) and DNase (0.015 mg/ml) in neurobasal medium (Gibco) for 30 min at 
37°C. Tissue was resuspended in neurobasal medium supplemented with B-27 additives (Gibco), 
L-glutamine (0.5 mM; Gibco) and glutamate (25 µM; Sigma-Aldrich), triturated and filtered 
twice through 70 μm pore nylon mesh filters. Neurons were plated and maintained in 
supplemented neurobasal medium. 
Neuron-mixed glia co-cultures 
All cultures were prepared in 24 well plates coated with poly-L-lysine lysine (0.5 mg/ml; Sigma-
Aldrich). In half of the wells neurons were cultured alone (indicated as neuron or neuron-alone 
cultures). In the remaining wells, we established neuron-mixed glia co-cultures (indicated as 
neuron-glia cultures) as described previously [153, 256]. Two deep midline grooves were made 
into the culture surface with a hot scalpel to inhibit the movement of glial cells between sides. 
Glial cells (2×10
5
 cells/well) were plated on one side of grooves by tilting the plate at a sufficient 
angle. After glia on one side of the grooves were confluent (10 d), neurons (0.25×10
5
 cells/well) 
were plated over the entire surface of the well. Neurons on one side of the grooves contact the 
glial bedlayer, while neurons on other side  grow on the culture surface, without direct glial 
contact. However, all neurons are exposed to glial conditioned medium. It is hard to visualize the 
neurite extensions when neurons are in contact with glia. Thus, for co-culture studies we  only 
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examined neurons growing on culture surface. Neuron and neuron-glia co-cultures were 
similarly maintained in supplemented neurobasal medium. Neurons were allowed to mature for 
6-7 d prior to treatment. 
Supernatant from HIV-infected cells 
H9 and U937 cells (ATCC, Manassas, VA; 0.5 × 10
5
 cells/ml) were cultured in RPMI-1640 
medium (Gibco) supplemented with 10% FBS, and stimulated with interleukin-2 (IL-2, 100 
ng/ml; Sigma-Aldrich), phytohaemagglutinin (PHA, 5 µg/ml; Sigma-Aldrich), and phorbol 12-
myristate 13-acetate (PMA, 100 ng/ml; only for U937 cells to induce differentiation; Sigma-
Aldrich), for 48 h. Stimulated cells were treated with polybrene (2 μg/ml; Sigma-Aldrich) for 30 
min at 37°C, resuspended in fresh medium and exposed respectively to HIV-1LAI and HIV-1SF162 
(p24 = 25-50 pg/ml; X4-tropic, HIV-1LAI, from Dr. Jean-Marie Bechet and Dr. Luc Montagnier 
[269, 270], and R5-tropic, HIV-1SF162, from Dr. Jay Levy [215] through NIH AIDS Research and 
Reference Reagent Program, Germantown, MD). After 5-7 d, supernatants (HIV
+
sup) were 
collected by filtering through a 0.20-μm filter, and viral productive infection was confirmed by 
quantifying HIV-p24 levels using ELISA (Advanced Bioscience Laboratories, Rockville, MD; 
typically a 3-5 fold increase in 5-7 d). Supernatants from uninfected/untreated H9 and U937 cells 
(Controlsup) were used as a control. Cell culture supernatants were aliquoted and stored at -80°C. 
Treatments 
Our previous studies have shown that R5-tropic HIV
+
sup induces neurotoxic effects in a 
concentration-dependent manner over a range of p24 levels (10-500 pg/ml). However, the 
interactions with morphine were significant only at lower HIV-exposure levels (p24 = 10 and 25 
pg/ml) [256]. Accordingly, the present studies used a HIV
+
sup exposure level of p24 = 25 pg/ml. 
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In addition, the neurotoxic effects mediated by purified virus (virus particles or virion; HIVvirion) 
at the same p24 exposure level were tested. HIV
+
sup/Controlsup or HIVvirion were added to 
neuronal cultures in the presence or absence of morphine sulfate (morphine; 500 nM; Sigma-
Aldrich) ± naloxone (1.5 µM; Sigma-Aldrich), a general opioid receptor antagonist. 
Neuron viability assessments 
After treatment, digital images of pre-selected neurons were recorded at 1 h interval for 72 h 
using a microscope with computer-regulated stage (Axio Vision 4.6; Zeiss Inc., Thornwood, NY) 
and controlled environment (37°C, 95% humidity and 5% CO2). Pre-selected neurons were 
visually assessed for viability in digital images at 6 h intervals. Cell death was confirmed using 
rigorous morphological criteria, including excessive neurite disintegration, cell body 
fragmentation, nuclear destruction and loss of phase brightness [151, 153, 218, 256]. Findings 
were reported as average percentage of neuron survival as a proportion of pre-treatment neuron 
count ± standard error of the mean (SEM). The effect of each treatment on neuron survival was 
analyzed using a repeated measures analysis of variance (ANOVA) followed by Duncan’s post 
hoc test (Statistica 8.0; StatSoft, Tulsa, OK). 
TUNEL assay 
At specified intervals after treatment, cells were rinsed with PBS (Gibco) and fixed overnight at 
4°C in 4% paraformaldehyde (Sigma-Aldrich). Cells were permeabilized at room temperature 
with 0.1% Triton-X 100 (Molecular Probes) and 0.1% BSA for 15 min, and subsequently 
blocked in 0.1% BSA (Invitrogen, Grand Island, NY) and 1% horse serum (Invitrogen) for 30 
min. Cells were labeled with Hoechst 33342 (Sigma-Aldrich) and TUNEL (terminal 
deoxynucleotidyl transferase dUTP nick end labeling; Roche Applied Sciences, Mannheim, 
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Germany). Cells were visualized and digital images were acquired using an Axio Observer Z.1 
microscope and Zen 2010 software (Zeiss Inc.). Neuronal apoptosis was assessed by manually 
counting the percentage of TUNEL(+) cells in digital images. 
Neurite length assessments 
At specified intervals after treatment cells were fixed, permeabilized, blocked and subsequently 
labeled with TUNEL and MAP-2 (Abcam, Cambridge, MA; ab32454). Cells were visualized and 
digital images were acquired. Neurite length was assessed in digital images using modified Sholl 
analysis. To specifically evaluate sub-lethal neurite length changes, only TUNEL(-) cells were 
examined. Sholl score was calculated by evaluating the cumulative intersections of MAP-2-
positive neurites with equidistant concentric circles of increasing radius, centered on the cell 
body [219]. Sholl score was converted into neurite length in µm using micrometer-scale 
calibration. 
ELISA  
Conditioned medium from HIV-1LAI-infected H9 cells or HIV-1SF162-infected U937 cells 
(HIV
+
sup) and uninfected H9 or U937 cells (Controlsup) were collected at day 5 and assessed for 
levels of interleukin 6 (IL-6), tumor necrosis factor α (TNFα), RANTES (also known as CCL5), 
and monocyte chemotactic protein-1 (MCP-1, also known as CCL2), using ELISA (R&D 
Systems, Minneapolis, MN). 3,3’,5,5’-tetramethylbenzidine (TMB) substrate was added for 
color development and plates were read at 450 nm using a PHERAstar microplate reader 
immediately after terminating the reaction. Protein levels were determined based on a standard 
curve. 
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Statistical Analyses 
All data were expressed as average ± SEM.  Unless otherwise indicated, data were statistically 
analyzed using a one-way ANOVA and Duncan’s post hoc test (Statistica 8.0; StatSoft). An α 
level of p < 0.05 was considered significant. 
Results 
Toxic effects of HIV
+
sup ± morphine in neuron cultures 
Cell survival was assessed using time-lapse imaging analysis (Fig. 3.1). In neuron-alone cultures, 
over the period of 72 h, HIV
+
sup significantly reduced neuron survival (Fig. 3.1B; Neuron panel). 
HIV
+
sup-mediated neuron death was significantly enhanced by morphine co-treatment, and the 
interactive effect of morphine was blocked by naloxone. Cell death was additionally confirmed 
using TUNEL-staining (Fig. 3.2). At all assessed time-points, HIV
+
sup significantly increased the 
percentage of TUNEL(+) neurons, which was augmented by morphine co-treatment (Fig. 3.2; 
Neuron panel). Interactive effects of morphine were blocked by naloxone. 
Since sublethal synaptic losses and neurite damage are considered to be a principal substrate for 
HAND [87-91], changes in neurite lengths were assessed using MAP-2 immunostaining 
followed by Sholl analysis (Fig. 3.3). To specifically evaluate sublethal neurite length changes, 
only TUNEL(-) cells were assessed instead of whole cell population, where inclusion of dead 
cells may distort the findings. In neuron-alone cultures,  HIV
+
sup significantly reduced neurite 
lengths at all assessed time-points.  No significant morphine interactions were noted (Fig. 3.3B; 
Neuron panel). 
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Role of glia in HIV
+
sup ± morphine-mediated neurotoxic effects 
HIV-1 itself rarely infects neurons [22, 47, 49, 58]; instead it induces indirect neurotoxic effects 
via release of cellular and viral toxic products from infected and activated glial cells [22, 62-65, 
251-253]. To assess the role of glia in HIV ± morphine-mediated neurotoxicity all treatments 
were carried out either in presence or absence of glia. In the presence of glia, HIV
+
sup ± 
morphine-mediated neuron death was significantly enhanced (Fig. 3.1B and 3.2; compare 
panels). The presence of glia did not cause any significant effect on HIV
+
sup ± morphine-
mediated neurite pruning (Fig. 3.3B; compare panels). In contrast, Controlsup-treated groups had 
significantly longer neurites. 
Secretion of cytokines/chemokines from HIV-1-infected T-cells 
The ‘indirect injury’ or ‘bystander damage’ hypothesis suggests that cytotoxic factors released 
from infected and activated cells cause neuronal injury [22, 62, 63]. Secretion of pro-
inflammatory factors was analyzed by assessing levels of cytokines/chemokines in conditioned 
medium from HIV-1LAI-infected H9 cells and HIV-1SF162-infected U937 cells using ELISA (Fig. 
3.4). After HIV-1-infection/exposure, with both viral strains, levels of IL-6, TNFα and RANTES 
were significantly increased. Infection of U937 cells with HIV-1SF162 caused significant increase 
in levels of MCP-1, but no significant change in MCP-1 levels was seen after infection of H9 
cells with HIV-1LAI.  
HIVvirion ± morphine-mediated neuronal death 
Many previous studies have shown that HIV-1 proteins as well as cytotoxic factors released from 
infected and activated cells induce neuronal damage [22, 62, 63, 67, 68, 71, 72]. But the 
neurotoxic effects produced by the virion itself and their interactions with opiates are not known. 
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HIV-1-virion (HIV-1LAI and HIV-1SF162) and morphine-mediated neuronal death was assessed 
using time-lapse imaging analysis (Fig. 3.5). In neuron-alone cultures, over the period of 72 h, no 
significant change in cell survival was seen after any treatments (Fig. 3.5; Neuron panel). In 
neuron-glia co-cultures, only HIV-1LAI alone significantly reduced neuron survival (Fig. 3.5; 
Neuron-glia panel). Both viral strains significantly induced cell death when co-treated with 
morphine. Presence of glia significantly increased HIV-1LAI + morphine-mediated effects. 
Discussion 
The neurotoxic effects and interactions with opiates of HIV-1LAI-supernatant (a X4 tropic strain) 
are quantitatively similar to that of HIV-1SF162 (a R5-tropic strain). This suggests that the toxic 
effects are largely attributable to cellular factors released from infected and activated cells 
instead of viral strain-specific factors. Secretion of certain cytokines/chemokines by H9 cells was 
elevated after infection/exposure to HIV-1LAI. Surprisingly, the cytokine/chemokine release 
profile of HIV-1LAI-infected H9 cells is almost similar to that of HIV-1SF162-infected U937 cells. 
This is the first demonstration that HIV-1LAI-virion alone induces deleterious effects on neurons; 
however, this occurs only in the presence of glia. These results extend prior findings regarding 
the role of glia in HIV-1 mediated neurotoxicity. 
Our results show that opiates interact with and exacerbate HIV
+
sup-mediated effects that result in 
neuronal death. But unlike cell death, opiates did not cause significant effects on HIV
+
sup-
mediated neurite pruning. From these results it can be interpreted that HIV-1 induces multiple 
pathways in neurons that result in different outcomes, and opiates interact with only certain 
pathways. HIV-1 alone or in concert with opiates induces release of various neurotoxic factors 
from glia [125, 147, 155], they also disturb neuron-supportive functions of glia, such as 
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glutamate buffering, free radical scavenging, release of neurotrophic factors and others [153, 
155, 248, 249].  Accordingly, our results also showed that HIV ± opiate mediated certain 
neurotoxic outcomes were exacerbated in presence of glia. Also severity of neurotoxic 
interactions between HIV-1 and opiates were enhanced in presence of glia. But HIV-1 and 
opiates showed some significant interactions in absence of glia too. Therefore, it can be 
concluded that though glia are important in HIV-1-opiate interactions, some interactions occur 
directly upon neurons.   
The deleterious effects of HIV-1LAI-supernatant on neurons are quantitatively similar to that of 
HIV-1SF162, as previously observed [256]. These results are in conflict with some previous 
studies [271, 272], where strain/tropism specific differences in neuropathological profiles have 
been seen. Also some previous studies have shown that drugs of abuse interact with HIV-1-
proteins in strain dependent manner [151, 268]. But in our studies we did not find quantitative 
differences between interactions of X4 and R5-tropic viral strain supernatants with opiates. 
Disparate findings may reflect the differences in response of neurons to individual viral proteins 
versus the multiple stimuli in HIV
+
sup. Our results suggest that neurotoxic effects mediated by 
HIV
+
sup are mainly attributed to common cytotoxic factors released from infected and activated 
cells instead of virion (viral strain) specific factors. These results support the theory that ‘indirect 
injury’ hypothesis is predominate over ‘direct injury’ hypothesis [62, 63]. 
Many previous studies have modeled HIV-1-neuropathalogy using individual viral proteins. But 
CNS of HIV-1-infected patients is not only exposed to individual viral proteins instead it is 
exposed to all cellular and viral factors and virions released from infected and/or activated cells. 
To model disease process more closely we used supernatant from HIV-1-infected cells. ‘Indirect 
injury’ or ‘bystander damage’ hypothesis suggest that HIV-1-mediated neurotoxic effects are 
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mainly attributed to cellular factors including cytokines, chemokines, excitotoxic factors and free 
radicals, released from infected and/or activated cells [22, 62-65, 251-253]. Our results show that 
after infection/exposure of H9 cells to HIV-1LAI secretion of certain cytokines including IL-6, 
TNFα and RANTES was enhanced. Surprisingly, cytokine/chemokine release profile, for 
assessed molecules, of HIV-1LAI-infected H9 cells is almost similar to that of HIV-1SF162-infected 
U937 cells; suggests reason behind the similarity between the neurotoxicity profiles of different 
viral strain-supernatants. Certain cellular factors are known to play role in HIV-1-mediated 
neurotoxicity [82, 273-276]. Although in current studies we have assessed only four 
cytokines/chemokines there must be other cellular factors released from infected and activated 
cells playing role in HIV-1-mediated neurotoxicity. 
Our studies demonstrated that HIVvirion induces neurotoxic effects but only in the presence of 
glia. Since we are using murine cell culture model, HIVvirion cannot infect the glia in our cultures. 
Thus, it can be predicted that HIVvirion may interact with glia and may induce release of cytotoxic 
factors and may also disturbs neuronal supportive functions of glia. These studies support and 
extend prior findings regarding the role of glia in HIV-1 mediated neurotoxicity [145, 153, 155, 
277]. Though we have used HIV
+
sup and HIVvirion at same p24 concentration our results show that 
HIV
+
sup is highly neurotoxic than HIVvirion. One of the obvious interpretations for these findings 
is that HIV
+
sup includes HIVvirion as well as cellular and viral factors released from infected and 
activated cells. Greater neurotoxic outcomes than seen with HIV
+
sup can be attributed to cellular 
and viral factors secreted from activated and infected cells. Also, the opiate-interactions seen 
with HIV
+
sup are not evident with HIVvirion. The neurotoxic interactions between HIV-1 and 
opiates are mainly caused by secreted factors instead of by HIVvirion. 
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Though we did not observe quantitative strain/tropism-specific differences in HIV
+
sup-mediated 
neurotoxic outcomes; surprisingly, HIVvirion displayed strain-specific differences. It can be 
concluded that in case of HIV
+
sup, strain specific-effects by HIVvirion are overshadowed by 
common secreted factors. Our results indicate that HIV-1LAI is slightly more neurotoxic than 
HIV-1SF162. Our results are in accord with some previous studies which also have showed that 
X4-tropic viral strains are more neurotoxic than R5-tropic strains [271, 272]. 
Overall our results show that opiates interact with and exacerbate HIV
+
sup-mediated effects that 
result in cell death in striatal neuron cultures. HIV-1 and opiate mediated selective neurotoxic 
outcomes were enhanced in the presence of glia, suggesting role of glia in these processes. 
Surprisingly neurotoxic outcomes profile by X4 and R5-tropic HIV-1-supernatants were 
quantitatively similar. Since assessed cytokine/chemokine release profile by X4-tropic virus 
infected T-cells and R5-tropic virus infected monocytes were almost similar HIV
+
sup-mediated 
neurotoxic outcomes are mainly attributed to cytotoxic factors released from infected and 
activated cells. Our results show that X4-tropic virion is slightly more neurotoxic than R5-tropic 
virion, may explain why co-receptor usage switch from CCR5 to CXCR4 is crucial in disease 
progression [264, 267].  
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Figures 
 
Figure 3.1. HIV
+
sup ± morphine-mediated neuronal death.  (A) Cells were repeatedly imaged 
for 72 h after treatments; digital images of the same cells/fields at 0, 24 and 72 h (white 
arrowheads indicate dead cells that were alive in previous image). (B) Cells were assessed for 
viability at 6 h intervals in digital images. The findings were reported as the average percentage 
of neuron survival as a proportion of pre-treatment neuron count ± SEM. Significance was 
analyzed by repeated measures ANOVA and Duncan’s post hoc test; n = 4 separate experiments 
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(at least 150 neurons per treatment group). In both culture systems, HIV
+
sup significantly reduced 
neuronal survival (*p < 0.05 vs. C), which was significantly augmented by morphine co-
treatment (
#
p < 0.05 vs. H). Interactive effects of morphine were blocked by naloxone. In the 
presence of glia, HIV
+
sup ± morphine-mediated neuronal death was significantly enhanced (
$
p < 
0.05 vs. corresponding treatment in neuron-alone cultures; compare panels). C = Controlsup; H = 
HIV
+
sup; M = morphine sulfate; N = naloxone (1.5 µM). 
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Figure 3.2. Neuronal apoptosis induced by HIV
+
sup ± morphine. Cells were fixed at specific 
intervals after treatment and labeled for Hoechst 33342 (blue) and TUNEL (red). The rate of 
neuron apoptosis was assessed by counting the percentage of TUNEL(+) cells, and reported as 
average % of TUNEL(+) cells ± SEM. Significance was analyzed by one-way ANOVA and 
Duncan’s post hoc test; n = 3 separate experiments. At all assessed time points, in both culture 
systems, HIV
+
sup significantly increased % of TUNEL(+) cells (*p < 0.05 vs. respective C 
group). Morphine significantly augmented HIV
+
sup-mediated neuronal apoptosis (
#
p < 0.05 vs. 
respective H group), interactive effects of morphine were blocked by naloxone. In the presence 
of glia, HIV
+
sup ± morphine-mediated neuronal apoptosis was significantly augmented (
$
p < 0.05 
vs. corresponding treatment in neuron cultures; compare panels). C = Controlsup; H = HIV
+
sup; M 
= morphine sulfate; N = naloxone. 
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Figure 3.3. HIV
+
sup ± morphine-mediated neurite damage. Cells were fixed at specific 
intervals after treatment and labeled for MAP-2 (green) and TUNEL (red).  (A) Digital images of 
neuronal cultures at 72 h after treatment. (B) The ‘Sholl score’ was assessed only for TUNEL(-) 
neurons in the digital images and converted into neurite length in µm via a micrometer-scale 
calibration. The findings were reported as average neurite length per neuron (µm) ± SEM. 
Significance was analyzed by one-way ANOVA and Duncan’s post hoc test from n = 3 separate 
experiments. At all time-points, in both culture systems, HIV
+
sup significantly reduced neurite 
length (*p < 0.05 vs. C), without any significant morphine interaction. In the presence of glia, 
Controlsup-treated groups showed significantly longer neurite length (
$
p < 0.05 vs. corresponding 
treatment in neuron cultures; compare panels). C = Controlsup; H = HIV
+
sup; M = morphine 
sulfate; N = naloxone. 
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Figure 3.4. Cytokines/chemokines secretion from HIV-1-infected cells. Conditioned medium 
from HIV-1LAI (X4)-infected H9 cells or HIV-1SF162 (R5)-infected U937 cells (HIV
+
sup) and 
uninfected H9 or U937 cells (Controlsup) at day 5 were collected and assessed for levels of IL-6, 
TNFα, RANTES and MCP-1, using ELISA. The findings were reported as average 
concentrations (pg/ml) ± SEM. Significance was analyzed using a one-way ANOVA and 
Duncan’s post hoc test, from n = 3 separate experiments. HIV-1-infection, with both viral strains, 
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elevated IL-6, TNFα and RANTES levels (*p < 0.05 vs. Controlsup). Infection of U937 cells with 
HIV-1SF162 caused significant increase levels of MCP-1, but no significant change in MCP-1 
levels was seen after infection of H9 cells with HIV-1LAI.  
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Figure 3.5. HIVvirion ± morphine-mediated neuronal death.  Neurons were repeatedly imaged 
for 72 h after treatment. Cells were assessed for viability at 6 h intervals in digital images. The 
findings were reported as the average percentage of neuron survival with respect to pre-treatment 
neuron count ± SEM. Significance was analyzed by repeated measures ANOVA and Duncan’s 
post hoc test, from n = 4 separate experiments. In neuron-alone cultures, no significant change in 
cell survival was seen after any treatments. In the presence of glia, only HIV-1LAI alone 
significantly reduced neuron survival (*p < 0.05 vs. C), while both viral strains significantly 
increased cell death when co-treated with morphine. Presence of glia significantly increased 
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HIV-1LAI + morphine-mediated neuronal death (
$
p < 0.05 vs. corresponding treatment in 
neuronal cultures; compare respective panels). C = Control (cell culture medium); H = HIVvirion 
(pure virus; HIV-1LAI and HIV-1SF162); M = morphine sulfate. 
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CHAPTER 4 
GSK3β-Activation is a Point of Convergence for HIV- and Opiate-Mediated Interactive 
Neurotoxicity. 
(This chapter is in preparation to submit for publication) 
Introduction 
Infection of the central nervous system (CNS) with human immunodeficiency virus-1 (HIV-1) 
occurs rapidly after primary peripheral infection [22-24, 278]. HIV-1 can induce a wide range of 
CNS deficits, collectively known as HIV-1-associated neurocognitive disorders (HAND); nearly 
50% of the HIV-1-infected individuals suffer from HAND [100-103]. Infected and/or activated 
glial and immune cells in the CNS release various viral and cellular factors that drive direct and 
indirect neuronal toxicity, leading to HAND [22, 62-65]. The advent of combination 
antiretroviral therapy (cART) has reduced the severity of HAND, but the prevalence of disease 
remains the same [88, 105-107, 111, 113, 254], likely due to longer patient survival [112], the 
relatively poor CNS penetrance of available antiretroviral drugs [88, 114], their neurotoxic 
effects [115], or a combination of all. 
Drug abuse is a major risk factor for HIV infection; nearly 30% of HIV
+
 patients have a history 
of drug abuse involving opiates [125, 127]. A large fraction of HIV
+
 patients are also exposed to 
opiates for treatment of AIDS-related chronic pain syndromes. Opiate drugs of abuse modulate 
immune function [132, 140, 255], and studies also have shown that opiates promote HIV-1 
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replication in vitro [135, 217]. Thus, opiate abuse not only increases the risk of HIV-infection 
but may also exacerbate disease progression. Since opiates by themselves have outcomes 
involved in neuronal dysfunction, such as blood brain barrier breakdown, immune and glial cell 
activation, and neuronal damage [139, 140, 154, 158], it can be predicted that opiate drug abuse 
might exacerbate HIV-1 pathogenesis in the CNS. Our previous work has shown that certain 
neurotoxic effects induced by the individual HIV-1 proteins, trans-activator of transcription (Tat) 
and glycoprotein 120 (gp120) [148, 149, 151-153], and by HIV
+
 supernatant (HIV
+
sup) [256], are 
enhanced by co-exposure to morphine, the major metabolite of heroin in the CNS [216]. This 
mimics co-morbid neurological effects observed in opiate-abusing HIV
+
 patients [160, 161]. 
Although there is a correlation between opiate drug abuse and HAND progression, the 
mechanisms that underlie interactions between HIV-1 and opiates remain obscure; the main aim 
of this work was to identify point(s) of convergence for HIV-1 and morphine signaling in 
neurons. 
Identified originally as a regulator of glycogen metabolism, glycogen synthase kinase-3β 
(GSK3β) is a central component of various signaling pathways in neurons including those 
affecting neuronal plasticity, gene expression, and cell survival [163, 165, 173]. Dysregulated 
GSK3β activity appears to be operant in various neuropathological conditions, including 
Alzheimer’s disease, Parkinson’s disease, schizophrenia, autism, and bipolar mood disorder, and 
pharmacological inhibition of GSK3β can ameliorate these diseases [163, 169, 173, 175, 176, 
180-183]. Previous studies have shown that HIV-1 induces neurotoxic effects through abnormal 
activation of GSK3β [174, 184-188], and that GSK3β is also linked to neuropathology seen with 
opiate-abusing patients [141, 142]. We therefore tested GSK3β-activation as a point of 
convergent signaling for interaction between HIV-1 and morphine.    
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Both lethal and sublethal effects of HIV
+
sup ± morphine treatments on neurons were assessed in 
populations, and also by time-lapse imaging of individual cells over 72 h. Multiple GSK3β 
inhibitors significantly reduced HIV-1-mediated neurotoxic outcomes, and also negated 
interactions with morphine that resulted in cell death. 
Materials and Methods 
All experimental procedures were reviewed and approved by the Virginia Commonwealth 
University Institutional Animal Care and Use Committee. 
Striatal neuron cultures 
Our culture model system uses striatal neurons because the striatum is a principal target of HIV-
1 and levels of opioid receptors in the striatum are relatively high [239, 240, 261]. Mouse striatal 
neurons were cultured as previously described [151, 153, 256, 279]. In brief, striata from E15-
E16 ICR (CD-1) mice (Charles River Laboratories International, Inc., Wilmington, MA) were 
dissected, minced and incubated with trypsin (2.5 mg/ml; Sigma-Aldrich, St. Louis, MO) and 
deoxyribonuclease (DNase; 0.015 mg/ml; Sigma-Aldrich) in neurobasal medium (Gibco, Grand 
Island, NY) for 30 min at 37°C. Tissue was resuspended in neurobasal medium supplemented 
with B-27 additives (Gibco), L-glutamine (0.5 mM; Gibco), glutamate (25 µM; Sigma-Aldrich) 
and Antibiotic-Antimycotic (Gibco), triturated, and filtered twice through 70 μm nylon mesh 
pore filters (BD Biosciences, San Jose, CA). Cells were seeded into culture plates (Corning Inc., 
Corning, NY) pre-coated with poly-L-lysine (0.5 mg/ml; Sigma-Aldrich), in supplemented 
neurobasal medium. Purity was determined by immunostaining for microtubule-associated 
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protein 2 (MAP-2, a dendrite marker; Abcam, Cambridge, MA; ab32454), and cultures were 
found to be > 80% neurons. 
HIV supernatants 
Cells of the acute monocytic leukemia cell line, THP1 (ATCC, Manassas, VA) were cultured at 
0.5 × 10
5
 cells/ml in RPMI-1640 medium (Gibco) supplemented with 10% fetal bovine serum 
(FBS; Gibco) and 100 U/ml Penicillin-Streptomycin (Gibco), and stimulated with interleukin-2 
(IL-2; 100 ng/ml; Sigma-Aldrich) and phytohaemagglutinin (PHA; 5 μg/ml; Sigma-Aldrich), for 
48 h. Stimulated cells were treated with polybrene (2 μg/ml; Sigma-Aldrich) for 30 min at 37°C, 
resuspended in fresh medium and exposed to HIV-1SF162 (p24 = 25-50 pg/ml; a R5-tropic HIV-1 
strain; from Dr. Jay Levy [215], through NIH AIDS Research and Reference Reagent Program, 
Germantown, MD). After 5 d, supernatants (HIV
+
sup) were collected by filtering through a 0.20-
μm filter, and viral infection was confirmed by quantifying HIV-p24 levels using ELISA 
(Advanced Bioscience Laboratories, Rockville, MD; typically a 3-5 fold increase in 5 d). 
Supernatants from uninfected/untreated THP1 cells (Controlsup) were used as a control. Cell 
culture supernatants were aliquoted and stored at -80°C. 
Treatments 
As opiates can enhance HIV replication [135, 217, 280], we assessed the interactive effects of 
morphine with cell-free, viral supernatant. Our previous studies showed that supernatants from 
HIV-infected cells induce neurotoxic effects in a concentration-dependent manner over a range 
of p24 levels (10-500 pg/ml), but the interactions with morphine were significant only at lower 
HIV-exposure levels (p24 = 10 and 25 pg/ml) [256]. Current studies used HIV
+
sup exposure level 
of p24 = 25 pg/ml. HIV
+
sup and Controlsup were added to neuronal cultures in the presence or 
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absence of morphine (morphine sulfate; Sigma-Aldrich), at a dose that maximally stimulate 
neuronal and glial μ-opioid receptors (MORs) in vitro (500 nM) [145, 147, 149, 151, 153, 220, 
221, 256]. To determine the role of GSK3β in HIV- and opiate-mediated neurotoxicity, HIV+sup 
± morphine treatments were carried out either in the presence or absence of a standard GSK3β 
inhibitor, sodium valproate (valproic acid, VPA; 1 mM; Sigma-Aldrich), or one of two small 
molecule inhibitors, SB415286 (10 µM; Sigma-Aldrich) and GSK3β inhibitor XXVI (XXVI; 1 
µM; EMD Millipore, Billerica, MA). 
TUNEL assay 
Cells were fixed in 4% paraformaldehyde (Sigma-Aldrich) overnight at 4°C, permeabilized in 
0.1% Triton-X 100 (Molecular Probes) and 0.1% BSA (Invitrogen, Grand Island, NY) for 15 
min, blocked in 0.1% BSA (Invitrogen, Grand Island, NY) and 1% horse serum (Invitrogen) for 
30 min, and subsequently labeled with Hoechst 33342 (Sigma-Aldrich) and TUNEL (terminal 
deoxynucleotidyl transferase dUTP nick end labeling; Roche Applied Sciences, Mannheim, 
Germany). Cells were visualized and digital images were acquired using the Axio Observer Z.1 
microscope and Zen 2010 software (Zeiss Inc., Thornwood, NY). Neuronal apoptosis was 
assessed by manually counting the percentage of TUNEL(+) cells. 
Assessment of neuron viability 
Time-lapse digital images of pre-selected neurons were captured at 1 h interval for 72 h after 
treatments using a microscope with computer-regulated stage (Axio Vision 4.6; Carl Zeiss Inc.) 
and controlled environment (37°C, 95% humidity, 5% CO2). In digital images, neurons were 
assessed for viability at 6 h intervals using rigorous morphological criteria confirming cell death, 
including cytoplasmic swelling, nuclear destruction, cell body fragmentation, excessive neurite 
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degeneration, and loss of phase brightness [151, 153, 218, 256, 279]. Findings were reported as 
the average percentage of neuronal survival, with respect to pre-treatment neuron count ± 
standard error of the mean (SEM). The effect of each treatment on neuronal survival was 
analyzed using a repeated measures analysis of variance (ANOVA) followed by Duncan’s post 
hoc test (Statistica 8.0; StatSoft, Tulsa, OK) from n = 3-5 experiments (at least 50 neurons per 
treatment group per experiment; total, 150-250 neurons per treatment group). 
Assessment of neuritic arborization 
Cells were fixed, permeabilized, blocked, and subsequently labeled for MAP-2 (Abcam), 
TUNEL (Roche Applied Sciences), and Hoechst 33342 (Sigma-Aldrich). Cells were visualized 
and digital images were acquired. Neuritic arborization was evaluated using Sholl analysis; a 
‘Sholl score’ was measured by counting the number of intersections of MAP-2-positive neurites 
with equidistant concentric circles of increasing radius, centered on the cell body [219]. To avoid 
the inclusion of dead cells, we specifically evaluated neuritic arborization changes by including 
only TUNEL(-) cells in our assessments. 
Immunoblotting 
Whole cell extracts were prepared using radioimmunoprecipitation assay (RIPA) buffer (Sigma-
Aldrich) with protease and phosphatase inhibitors (Roche Applied Sciences), and total protein 
concentrations were determined by bicinchoninic acid (BCA) assay (Thermo Fisher Scientific, 
Rockford, IL). Cell lysates containing equal amounts of total protein (~5-10 μg) were heated at 
100º C for 5 minutes in laemmli buffer (Sigma-Aldrich), electrophoretically separated on a 10% 
SDS-polyacrylamide gels (Bio-Rad, Hercules, CA), and transferred onto polyvinylidene 
difluoride (PVDF) membranes (Bio-Rad). Membranes were incubated with primary antibodies to 
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phospho-GSK3β-Ser9 (Cell Signaling Technology, Danvers, MA; 5558), GSK3β (Cell Signaling 
Technology; 9832), β-Catenin (Cell Signaling Technology; 9562), glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH; Abcam; ab8245), MAP-2 (Abcam; ab32454) and postsynaptic density 
protein 95 (PSD-95; UC Davis/NIH NeuroMab Facility, Davis, CA; 73-028). Appropriate 
horseradish peroxidase-conjugated secondary antibodies (SouthernBiotech, Birmingham, AL) 
were used. Membranes were detected using SuperSignal
®
 West Femto Maximum Sensitivity 
Substrate (Thermo Fisher Scientific), and visualized using a Kodak Image Station 440CF. 
Statistical Analyses 
All data were expressed as average ± SEM. Unless otherwise indicated, data were analyzed 
statistically using a one-way ANOVA followed by Duncan’s post hoc test using Statistica 8.0 
(StatSoft); an α level of p < 0.05 was considered significant. 
Results 
HIV- and morphine-mediated GSK3β activation 
GSK3β activation/inactivation was assessed at 4 h after treatments. Cell lysates were 
immunoblotted for phospho-GSK3β-Ser9 (p-GSK3β-S9; an inactive form of GSK3β [165, 173, 
175, 233]), GSK3β (total GSK3β; t-GSK3β), β-Catenin, and GAPDH (Fig. 4.1). HIV+sup, with or 
without morphine, significantly decreased p-GSK3β-S9 (normalized with t-GSK3β; p-GSK3β-
S9/t-GSK3β; Fig. 4.1A), suggesting an increase in GSK3β activation. VPA significantly 
abrogated HIV
+
sup ± morphine-mediated effects. β-Catenin is a downstream target of GSK3β; 
active GSK3β phosphorylates β-Catenin and initiates rapid ubiquitin-mediated degradation by 
the proteasome [173, 175, 189]. HIV
+
sup, with or without morphine, significantly reduced β-
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Catenin levels (Fig. 4.1B), suggesting an enhancement in GSK3β activity. VPA completely 
inhibited the effect of HIV
+
sup + morphine and partially inhibited the effect of HIV
+
sup alone, 
returning both to levels that were not different from control levels. 
Opiates are known to induce time-dependent effects on GSK3β activation [205, 206]. Since 
significant individual or interactive effects of morphine were not detected at 4 h, HIV
+
sup and 
morphine-mediated effects were assessed at longer time intervals (Fig. 4.2). At all assessed time 
points (12, 24, and 72 h), HIV
+
sup significantly reduced p-GSK3β-S9. At 24 and 72 h, morphine 
alone also induced significant loss of p-GSK3β-S9, but a significant interaction with HIV+sup was 
seen only at 24 h. 
Role of GSK3β in HIV ± morphine-mediated cell death 
Neurons exposed to morphine and/or VPA had survival values equivalent to control, while all 
groups treated with HIV
+
sup showed significantly reduced neuronal survival (time-lapse imaging 
analysis; Fig. 4.3B). Morphine significantly enhanced HIV
+
sup-mediated neuronal death. HIV
+
sup 
± morphine-mediated effects were partially, but significantly, reversed by VPA co-treatment. 
The survival of neurons treated with ‘HIV+sup + VPA’ and ‘HIV
+
sup + morphine + VPA’ was not 
significantly different, showing that VPA effectively negated any HIV
+
sup-morphine interactions. 
Cell death was additionally confirmed using TUNEL staining (Fig. 4.3C). HIV
+
sup induced a 
significant increase in TUNEL(+) neurons, which was augmented by morphine co-treatment. 
HIV
+
sup ± morphine-mediated effects were partially, but significantly, reversed by VPA co-
treatment. As seen for the time-lapse analyses, VPA also nullified the interactions between 
HIV
+
sup and morphine.  
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Role of GSK3β in HIV ± morphine-mediated changes in neuritic arborization, MAP-2 and 
PSD-95 
Since neurite degeneration and synapse losses are the major substrate for HAND [87-91] we 
assessed changes in neuritic arborization using MAP-2 immunostaining followed by Sholl 
analysis (Fig. 4.4A and B). At 72 h, HIV
+
sup induced a significant reduction in neuritic 
arborization (Fig. 4.4B). There was no morphine interaction, and the HIV effect was partially, 
but significantly, reversed by VPA co-treatment. Neuritic/synaptic degeneration was additionally 
confirmed by immunoblotting for MAP-2 and PSD-95 (Fig. 4.4C and D). At 72 h, HIV
+
sup 
significantly decreased MAP-2. Similar to the Sholl analysis, there was no morphine interaction 
(Fig. 4.4C), and VPA significantly abrogated HIV
+
sup-mediated loss of MAP-2. HIV
+
sup also 
induced a significant loss in PSD-95, but in this case there was an increased loss with morphine 
co-treatment (Fig. 4.4D). VPA partially, but significantly, reversed HIV
+
sup ± morphine effects 
on PSD-95. The HIV-morphine interaction on PSD-95 levels was maintained in the presence of 
VPA. 
Effects of small molecule GSK3β-inhibitors 
The role of GSK3β activation in HIV+sup ± morphine-mediated neurotoxicity was confirmed by 
the additional use of the small molecule GSK3β-inhibitors, SB415286 or XXVI (Fig. 4.5). Both 
small molecule inhibitors partially, but significantly, reduced HIV
+
sup ± morphine-mediated 
neuronal death, and also abrogated HIV
+
sup-morphine interactions (Fig. 4.5A and B). Both 
inhibitors reversed the effect of HIV
+
sup on neurite loss, although SB415286 only resulted in 
partial recovery (Fig. 4.5C). 
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Discussion 
The current studies show that GSK3β inhibitors reduce many neurotoxic effects of HIV+sup ± 
morphine, including cell death, neurite pruning, and loss of structural and functional proteins, 
indicating that GSK3β plays an active role in multiple, degenerative processes. Interactions 
between HIV
+
sup and morphine enhanced neuronal death and increased the loss of PSD95, 
similar to interactions that we have previously reported for HIV proteins and morphine [148, 
149, 151-153].  Importantly, GSK3β-inhibitors entirely negated the HIV-morphine interactive 
effect on neuron death, demonstrating for the first time that GSK3β-activation is an important 
point of convergence for neurotoxic interactions between HIV and opiates. GSK3β-inhibitors 
only partially reversed certain effects of HIV
+
sup, and did not disrupt HIV-morphine interactive 
effects on PSD95, indicating the likely involvement of other signaling pathways in various 
aspects of HIV± morphine-related neurotoxicity. 
Though HIV-1 induces profound changes in neuronal morphology, function, and survival, the 
virus itself rarely infects neurons [22, 47, 49, 58]; instead, infected and activated glial cells 
produce cellular and viral products that drive secondary toxicity in neurons, known as ‘bystander 
damage’ [22, 62-65]. Our previous studies have shown that glia play a crucial role in 
determining the extent of neurotoxic interactions between the HIV-1 proteins, Tat or gp120 and 
opiates [151, 153] as well as those between supernatant from HIV-1 infected cells and opiates 
[256]. As the present studies primarily focus on understanding the pathway(s) in neurons that 
underlie HIV-1 and opiate interactions, we excluded glia from our culture model system. Still, it 
must be remembered that glial mechanisms play important roles in HIV- and opiate-mediated 
neurotoxicity. 
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In accord with many previous studies [174, 184-188], our results show that HIV
+
sup induces 
GSK3β-activation, and that treatments to inhibit GSK3β activation ameliorate HIV+sup-mediated 
neurotoxic effects. GSK3β-activation clearly plays a central role in HIV-1-associated neuronal 
damage. Abnormally active GSK3β can promote neuronal damage via dysregulating 
function/stability of various structural, metabolic, and signaling proteins, including tau, β-
catenin, MAP-2, activator protein 1 (AP-1), cyclic AMP response element binding protein 
(CREB), nuclear factor-kappa B (NF-κB), heat shock factor-1 (HSF-1), and others. [163, 165, 
166, 175]. In our study, certain neurotoxic outcomes due to HIV
+
sup were only partially reversed 
by co-treatment with GSK3β inhibitors, suggesting the involvement of other factors such as 
mitogen-activated protein kinase 10 (MAPK10), double-stranded RNA-activated protein kinase 
(PKR), and cyclin-dependent kinase 5 (CDK5) [174, 281, 282]. 
Studies from the brains of opiate-abusing patients have indirectly implicated GSK3β-activation 
in opiate-associated neuropathology [141, 142]. However, previous studies have disagreed on 
whether opiates induce GSK3β activation [205, 206] or cause inactivation [208, 209]. Opiates 
induce effects on GSK3β-activity in a dose- and time-dependent manner [206]. Acute activation 
of µ-opioid receptors (MORs) inhibits GSK3β activity via phosphatidylinositol 3 kinase 
(PI3K)/Akt signaling pathway [209], while chronic activation of MORs elevates GSK3β activity 
[205, 206], may be through transient increase in intracellular calcium [205, 283, 284]. In accord 
with these studies, our results also show that morphine exerts time-dependent effects on GSK3β 
activation (Fig. 4.1 and 4.2). At earlier time points (4 and 12 h) morphine effects were not 
observed, but at later time points (24 and 72 h) morphine significantly induced GSK3β 
activation. 
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At 24 h, morphine significantly augmented HIV
+
sup-mediated GSK3β activation (Fig. 4.2), but 
this transient additive/interactive effect of morphine was not seen at 72 h. By 72 h, HIV
+
sup + 
morphine treatment induced nearly 50% cell death (Fig. 4.3 and 4.5). Therefore, may be due to 
excessive cell death or selective loss of MOR-expressing neurons interactive effect of morphine 
is vanished. Though at 72 h, no significant interactive effect of morphine was seen, overall 
tendency of morphine is to induce GSK3β activation.  
Although there was no additive/interactive effect of morphine on p-GSK3β at 72 h, morphine did 
exacerbate some neurotoxic effects of HIV
+
sup at that time (cell death and loss of PSD-95). This 
discordance may be due to a difference in the time-frame of the ‘cause’ and the ‘effect’. The 
morphine-mediated interactive elevation in GSK3β activity seen at 24 h is the cause, resulting in 
an ‘effect’, aggravation of neurotoxic outcomes that is seen at a somewhat later time.  
Certain neurotoxic outcomes of HIV
+
sup were completely reversed by VPA co-treatment (loss of 
MAP-2; Fig. 4.4C), while some were only partially reversed (cell death and loss of PSD-95; Fig. 
4.3 and 4.4D). In terms of HIV
+
sup-morphine interactions, VPA co-treatment negated the 
interaction that augmented neuronal death (Fig. 4.3), but did not reduce the interaction that 
augmented PSD-95 loss (Fig. 4.4D). These discrepancies likely reflect the role(s) of other 
molecules or pathways, which, given the multiple downstream pathways and events triggered by 
opiates, HIV virions, and factors secreted from HIV-infected cells, is predictable. For example, 
CDK5, like GSK3β, is known to be involved in both HIV- and opiate-associated neuropathology 
[141, 174, 207, 281, 285], and might be a likely candidate in this regard.  
In previous studies, VPA has significantly ameliorated HIV-mediated neurotoxic outcomes both 
in experimental models [174, 184, 204] and in patients [203]. Though VPA is a potent GSK3β 
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inhibitor, it is not a specific inhibitor; VPA targets additional molecules/pathways, including 
HDAC, Na
+
 channels, Ca
2+
 channels, voltage-gated K
+
 channels, GSK3α, and others [286]. 
Therefore, we also tested effects of the small molecule GSK3β-inhibitors SB415286 and XXVI 
which have much greater target specificity. Since both small molecule inhibitors similarly 
inhibited HIV
+
sup ± morphine-mediated neurotoxic outcomes (Fig. 4.5), the role of GSK3β in 
these processes is confirmed. 
HIV
+
 patients who abuse opiates show more serious neuropathologies and behavioral and 
cognitive deficits [160, 161]. The current work implies that GSK3β-mediated signaling 
pathway(s) are mechanistic in HIV-opiate interactions. Our recent studies have shown that the 
continuous presence of morphine limits the ability of neurons to recover from an HIV insults, 
even after HIV is removed [256]. In the post-cART era those studies are quite critical because 
they suggest that continual exposure to opiate drugs of abuse, and perhaps also opiates 
prescribed for pain, can limit the reversibility of HIV insults in the CNS. If true, this will impact 
the effectiveness of neurotherapeutic efforts. Based on the current findings it is reasonable to 
predict that opiates might limit neurite recovery after HIV insults via a GSK3β-mediated 
signaling mechanism. A recent study by Kehn-Hall et al. has shown that 6BIOder, a novel 
GSK3β-inhibitor, inhibits HIV-1 replication [201]. Also GSK3β is identified as a central 
mediator of pro-inflammatory processes in CNS [169, 198-200]. Thus, therapeutically targeting 
GSK3β along with cART may further diminish viral replication, neuroinflammation and 
neuronal damage, and may improve recovery. 
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Figures 
 
Figure 4.1. HIV
+
sup ± morphine-mediated GSK3β activation. At 4 h after treatment, cells 
were lysed and protein levels were detected using immunoblot analysis. Findings were reported 
as average normalized protein levels (% control) ± SEM. Significance was analyzed by one-way 
ANOVA and Duncan’s post hoc test; n = 4 separate experiments. (A) Immunoblotting for 
phospho-GSK3β-Ser9 (p-GSKβ-S9) and total GSK3β (t-GSK3β); levels of p-GSKβ-S9 were 
normalized with t-GSK3β (p-GSKβ-S9/t-GSK3β). HIV+sup significantly reduced p-GSK3β-S9 
(*p < 0.05 vs. Control), without any significant morphine interaction. VPA significantly 
abrogated HIV
+
sup ± morphine-mediated effects (
#
p < 0.05). (B) Immunoblotting for β-catenin 
and GAPDH; levels of β-catenin were normalized with GAPDH (β-catenin/GAPDH). HIV+sup 
significantly decreased β-catenin (*p < 0.05 vs. Control) without any morphine interaction. VPA 
restored β-catenin levels to control values (#p < 0.05), although in the case of neurons treated 
with HIV
+
sup alone the effect was somewhat less significant (HIV
 
+ VPA was not different from 
either HIV or control). Control = controlsup; HIV = HIV
+
sup; Mor = morphine sulfate; VPA = 
sodium valproate. 
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Figure 4.2. HIV
+
sup- and morphine-mediated interactive effects on GSK3β-activation. At 
12, 24 and 72 h after treatment, cells were lysed and immunoblotted for p-GSKβ-S9 and t-
GSK3β. Findings were reported as average levels of p-GSKβ-S9 normalized with t-GSK3β (p-
GSKβ-S9/t-GSK3β) as a percentage of control values ± SEM. Significance was analyzed by one-
way ANOVA and Duncan’s post hoc test; n = 3 separate experiments. At all times, HIV+sup 
significantly reduced p-GSK3β-S9 (*p < 0.05 vs. Control). At 24 and 72 h, morphine alone also 
induced significant loss of p-GSK3β-S9. A significant interaction with HIV+sup was seen at 24 h 
(
$
p< 0.05). Control = controlsup; HIV = HIV
+
sup; Mor = morphine sulfate. 
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Figure 4.3. Role of GSK3β in HIV+sup ± morphine-mediated cell death. (A) Cells were 
repeatedly imaged for 72 h after treatments. Digital images show the same cells/fields at 0, 24 
and 72 h (white arrowheads indicate dead cells that were alive in previous image). (B) Cells were 
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assessed for viability at 6 h intervals in digital images. Findings were reported as the average 
percentage of neuronal survival as a proportion of pre-treatment neuron count ± SEM. 
Significance was analyzed by repeated measures ANOVA and Duncan’s post hoc test; n = 3 
separate experiments (at least 150 neurons per treatment group). HIV
+
sup significantly reduced 
neuronal survival (*p < 0.05 vs. Control), which was significantly augmented by morphine co-
treatment (
$
p < 0.05). HIV
+
sup ± morphine-mediated effects were partially, but significantly, 
reversed by VPA (
#
p < 0.05). VPA also effectively negated HIV
+
sup-morphine interactions. (C) 
At 72 h after treatment, cells were fixed, permeabilized, and labeled for TUNEL and Hoechst 
33342. The rate of neuronal apoptosis was reported as the average percentage of TUNEL(+) cells 
± SEM. Significance was analyzed by one-way ANOVA and Duncan’s post hoc test; n = 3 
separate experiments. HIV
+
sup significantly increased the percentage of TUNEL(+) cells (*p < 
0.05 vs. Control), and morphine augmented the effect (
$
p < 0.05). HIV
+
sup ± morphine-mediated 
effects were partially, but significantly, reversed by VPA co-treatment (
#
p < 0.05), and VPA 
negated interactions between HIV
+
sup and morphine. Control = controlsup; HIV = HIV
+
sup; Mor = 
morphine sulfate; VPA = sodium valproate. 
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Figure 4.4. Role of GSK3β in HIV+sup ± morphine-mediated changes in neuritic 
arborization, MAP-2 and PSD-95. (A) At 72 h after treatment, cells were fixed, permeabilized, 
and labeled for MAP-2 (green), TUNEL (red) and Hoechst 33342 (blue) (B) Neurite arborization 
was measured by Sholl analysis in digital images of TUNEL(-) neurons. The findings were 
reported as average Sholl score ± SEM. HIV
+
sup significantly reduced the Sholl score (*p < 0.05 
vs. Control), without any significant morphine interaction. HIV
+
sup ± morphine-mediated effects 
were partially, but significantly, reversed by VPA co-treatment (
#
p < 0.05). (C) At 72 h after 
treatments, cells were lysed and immunoblotted for MAP-2 and GAPDH. Findings were reported 
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as average normalized MAP-2 (% control) ± SEM. HIV
+
sup, with or without morphine, 
significantly reduced MAP-2 (*p < 0.05 vs. Control). VPA significantly inhibited HIV
+
sup ± 
morphine-mediated effects (
#
p < 0.05). (D) Cell lysates were immunoblotted for PSD-95 and 
GAPDH. Findings were reported as average normalized PSD-95 (% control) ± SEM. HIV
+
sup 
induced a significant loss of PSD-95 (*p < 0.05 vs. Control), which was augmented by morphine 
co-treatment (
$
p < 0.05). HIV
+
sup ± morphine-mediated effects were partially, but significantly, 
reversed by VPA co-treatment (
#
p < 0.05). Even in the presence of VPA, morphine significantly 
augmented the effects of HIV
+
sup-mediated effects (
$
p < 0.05). In all studies, significance was 
analyzed by one-way ANOVA and Duncan’s post hoc test, from n = 3 separate experiments. 
Control = controlsup; HIV = HIV
+
sup; Mor = morphine sulfate; VPA = sodium valproate. 
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Figure 4.5. Effects of small molecule GSK3β-inhibitors. (A) Cell viability was assessed by 
time-lapse imaging analysis. Neurons exposed to ‘Control + SB’, ‘Control + XXVI’, ‘Mor’, 
‘Mor + SB’ and ‘Mor + XXVI’ treatments had survival equivalent to ‘Control’  but are not 
shown in the figure to highlight other groups. HIV
+
sup significantly reduced neuronal survival (*p 
< 0.05 vs. Control), with a significant morphine interaction (
$
p < 0.05). The effects of HIV
+
sup 
were partially, but significantly, reversed by both small molecule inhibitors (
#
p < 0.05 vs. 
respective HIV
 
or HIV + Mor). Both SB415286 and XXVI also effectively negated interactions 
between HIV
+
sup and morphine. (B) Cell death was examined using TUNEL-staining. HIV
+
sup 
significantly increased the percentage of TUNEL(+) cells (*p < 0.05 vs. Control), with a 
significant morphine interaction (
$
p < 0.05). Both small molecule inhibitors partially reversed 
HIV
+
sup ± morphine-mediated effects (
#
p < 0.05) and also eradicated the HIV
+
sup-morphine 
interaction. (C) Neuritic arborization was evaluated using MAP-2 immunostaining and Sholl 
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analysis. HIV
+
sup significantly reduced the Sholl score (*p < 0.05 vs. Control) without a 
morphine interaction. All losses in arborization were partially, but significantly, reversed by both 
small molecule inhibitors (
#
p < 0.05), except that XXVI completely reversed the effect of 
HIV
+
sup. Control = controlsup; HIV = HIV
+
sup; Mor = morphine sulfate; SB = SB415286; XXVI = 
GSK3β inhibitor XXVI. 
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CHAPTER 5 
Conclusions 
HIV-1 disturbs normal immune system functioning and leads to AIDS. Soon after initial 
systemic infection HIV-1 can crossover BBB and enter into CNS [22-24, 278]. HIV-1 can induce 
a wide range of neurocognitive deficits, collectively known as HAND. Nearly 50% of HIV-1
+
 
patients suffer from HAND [100-103]. After the advent of cART, the survival rates and health 
status of AIDS patients has been tremendously improved [105, 111, 112]. Though cART has 
reduced the severity of HIV-associated CNS deficits, the overall prevalence of the disease 
remains the same [88, 105-107, 111]. 
Injection drug abuse is a major cause of acquiring HIV-infection. Nearly 50% of HIV
+
-patients 
have a history of drug abuse, commonly involving opiates [125, 127]. Opiate abusing HIV
+
-
patients have high risk for faster progression of AIDS [132, 135, 140, 217, 255]. Many 
experimental evidences have shown that opiates exacerbate HIV-1-mediated neurotoxic 
outcomes on CNS cells and tissues [125, 145, 147-151, 153], mimics co-morbid neurological 
deficits observed in opiate abusing HIV
+
-patients [160, 161]. Though many experimental and 
epidemiological findings have indicated a link between opiate drug abuse and HAND 
progression, the extent to which opiates exacerbate neurological deficits is still controversial. 
In our current studies, we have tried to determine: (a) whether opiates have any effect HIV-1-
mediated neurotoxic outcomes; (b) strain/tropism-specific differences in HIV-1 mediated 
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neurotoxicity and interactions with opiates; (c) point(s) of convergence for HIV-1 and opiate 
mediated signaling. 
Many previous studies have modeled HIV-1-mediated neuropathology using individual viral 
proteins. But the CNS of HIV-1-infected patients is not only exposed to individual viral proteins 
instead it is exposed to all cytotoxins, virotoxins and virus particles released from infected and/or 
activated cells. To model disease process more closely, we have used supernatant from HIV-1-
infected cells. R5-tropic HIV-1 strains are predominant in CNS [213, 214]. Therefore, in chapter 
2 we used a R5-tropic strain, HIV-1SF162. We assessed different neurotoxic outcomes mediated 
by HIV
+
sup, in the presence or absence of morphine. 
Our results showed that HIV
+
sup induce neuronal death in concentration-dependent manner. But 
interestingly, significant interactive effects of morphine were seen only at lower HIV-1 exposure 
levels. Interactive effects of morphine may get masked due to excessive cell death at higher HIV-
1 exposure levels. These results may explain controversy concerning the role of opiates in 
severity of HAND. In addition, our results caution that patients receiving cART may be highly 
vulnerable to opiate interactions since cART has greatly reduced the viral load [105, 111, 112]. 
Our results showed that opiates interact with and exacerbate only selective neurotoxic outcomes 
by HIV-1 (compare neuronal death and neurite pruning results). Suggesting that HIV- and 
opiate-mediated neurotoxicity is induced via multiple pathways that may lead to different 
outcomes, and interactions occur for selective pathways only. Importantly, our results showed 
that morphine limits neurite recovery after HIV-1-insults. Altogether, our results suggest that 
continual exposure to opiate drugs of abuse may adversely impact the neurotherapeutic efforts of 
cART.  
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Glia played dual role in HIV-1-mediated neurotoxicity. On one hand, HIV-1 ± morphine-
mediated neuronal death was exacerbated in presence of glia; by contrast, glia enhanced neurite 
outgrowth when HIV was removed. Damaging effects by glia in presence of HIV-1 are largely 
attributable to the enhanced release of pro-inflammatory cytokines, and neurotrophic effects after 
removal of HIV may due to the rebound in release of growth factors. 
We propagated HIV-1 in human cell lines, but due to inconsistency in availability of human 
brain cells from specific regions, we used murine cell culture model system. Therefore, we need 
to keep in mind the issue of species mixing while interpreting results from our model system. 
Cell culture model systems are easy to maintain and manipulate and provide a general idea about 
actual in vivo system. However, we need to be cautious when extrapolating these results because 
there are various additional factors present in actual in vivo system which may interfere with 
these processes. 
Though during early stage of infection R5-tropic HIV-1 strains are predominant during late stage 
of disease X4-tropic strains are predominant; co-receptor usage switch from CCR5 to CXCR4 is 
crucial in disease progression to AIDS [263-267]. Some previous studies have shown that HIV-1 
induces neurotoxic effects and interacts with drugs of abuse in strain/tropism-specific manner 
[151, 268, 271, 272]. Therefore, in chapter 3 we tried to compare neurotoxic effects of HIV-1LAI 
(X4-tropic) and HIV-1SF162 (R5-tropic) and their interactions with opiates. 
Surprisingly, our results showed that the neurotoxic effects and interactions with opiates by X4 
and R5-tropic HIV-1-supernatants are quantitatively similar. Also cytokine/chemokine release 
profile of X4 and R5-tropic HIV-1-infected cells is almost similar. Altogether our results suggest 
that HIV-1-supernatant mediated neurotoxicity is mainly attributed to common cytotoxic factors 
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released from infected and/or activated cells instead of viral strain specific factors. Our results 
support ‘indirect injury’ or ‘bystander damage’ hypothesis. 
Interestingly, studies with HIV-1 virion showed strain-specific differences. May be in case of 
HIV-1-superntant these strain-specific differences are overshadowed by other cytotoxic factors. 
But in case of HIV-1 virion neuronal death was observed in the presence of glia only, confirms 
role of glia/glia-activation in HIV-1 mediated neurotoxicity. In accord with some previous 
studies [271, 272] our results showed that HIV-1LAI (X4-tropic) is slightly more neurotoxic than 
HIV-1SF162 (R5-tropic); these results may explain why co-receptor usage switch is crucial in 
disease progression [264, 267]. 
Though many previous studies have indicated a link between opiate drug abuse and HAND 
progression [125, 145, 147-151, 153, 160, 161], the mechanisms that underlie interactions 
between HIV-1 and opiates remain largely obscure. Previous studies have shown that HIV-1 
induces neurotoxic effects via abnormal activation of GSK3β [174, 184-188], GSK3β is also 
linked to neuropathology seen in opiate abusing patients [141, 142]. Therefore, in chapter 4, we 
tested role of GSK3β as a point of convergence for interactions between HIV-1 and morphine. 
Our results showed that HIV-1 induces GSK3β activation; morphine alone and in concert with 
HIV-1 induced GSK3β activation in time-dependent manner. Multiple GSK3β-inhibitors 
significantly reduced HIV-1 ± morphine-mediated neurotoxic outcomes, suggesting role of 
GSK3β in these processes. Importantly, GSK3β-inhibitors negated selective neurotoxic 
interactions between HIV-1 and morphine. Since certain neurotoxic outcomes and interactive 
effects were only partially reversed also the role of other factors, such as CDK5,  is suggested. 
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Altogether our results suggest that GSK3β is a potential therapeutic target for HIV-1- and opiate-
mediated neurocognitive deficits.   
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